

Julio Alberto Ramirez, M.D., F.A.C.P.
Professor of Medicine
Chief, Division of Infectious Diseases, University of Louisville
501 E. Broadway
MedCenter One, Suite 100
University of Louisville
Louisville, KY 40202

Nationality	United States of America
Residential Address	324 East Main Street, Unit 513, Louisville, KY 40202
Office Telephone	502/852-1148
Office Fax	502/852-1147
E-mail Address	J.ramirez@louisville.edu

EDUCATIONAL BACKGROUND

B.A., National College 1964-1969	La Plata National University La Plata, Argentina
M.D., Medical School 1970-1976	La Plata National University, School of Medical Science La Plata, Argentina
Residency in Internal Medicine 1976-1977	La Plata National University, Postgraduate Medical School La Plata, Argentina
Fellowship in Critical Care Medicine 1977-1978	National Institute of Respiratory Diseases and Thoracic Surgery Santiago, Chile
Residency in Internal Medicine 1984-1987	New York Medical College, Lincoln Medical Center New York, NY
Fellowship in Infectious Diseases 1987-1989	University of Louisville, School of Medicine Louisville, KY

TITLES AND CERTIFICATION

M.D. 1975	La Plata National University, School of Medical Science Buenos Aires, Argentina
Diplomate in Critical Care Medicine 1981	Province of Buenos Aires Medical College Certifying Exam Buenos Aires, Argentina
Diplomate in Internal Medicine 1987	American Board Certifying Exam #114276 Louisville, KY
Diplomate in Infectious Diseases 1990 2001 2011	American Board of Subspecialties Certifying Exam #114276 Cleveland, OH Atlanta, GA Louisville, KY

ACADEMIC APPOINTMENTS

2001-Present	Professor of Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, KY
2012-Present	Associate Professor in Microbiology and Immunology, University of Louisville School of Medicine, Louisville, KY
1995-2001	Associate Professor of Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, KY
1989-1995	Assistant Professor of Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, KY
1998-2001	Associate Clinical Professor, Department of Pathology, University of Louisville School of Medicine, Louisville, KY

CURRENT LEADERSHIP POSITIONS

1995-Present	Chief, Division of Infectious Diseases, University of Louisville School of Medicine, Louisville, KY
1992-Present	Director, Infectious Diseases Fellowship Training Program, University of Louisville School of Medicine, Louisville, KY
1999-Present	Director, Community Acquired Pneumonia Organization (CAPO), Global network to foster research in pneumonia and influenza
2007-Present	Director, Bone and Joint Infection Program, University of Louisville Hospital, Louisville, KY
2009-Present	Director, HIV Program, University of Louisville School of Medicine, Louisville, KY
2011-Present	Director, Center of Excellence for Research in Infectious Diseases (CERID), Department of Medicine University of Louisville, Louisville, KY

PROFESSIONAL CAREER

1979-1981	Staff Physician, Intensive Care Unit. Dr. R. Rossi Hospital La Plata, Argentina
1981-1984	Staff Physician, Intensive Care Unit. Gral San Martin, La Plata University Hospital La Plata, Argentina
1981-1984	Staff Physician, Intensive Care Unit. Instituto Diagnostico La Plata Argentina
1989-Present	Staff Physician, Consultant in Infectious Diseases, University of Louisville Hospital Louisville, KY
1989-Present	Staff Physician, Consultant in Infectious Diseases, Robley Rex VA Medical Center Louisville, KY
1990-Present	Staff Physician, Consultant in Infectious Diseases, Jewish Hospital Louisville, KY
1990-Present	Staff Physician, Consultant in Infectious Diseases, Norton Hospital Louisville, KY

PROFESSIONAL AFFILIATIONS

Alpha Omega Alpha Honor Medical Society
American Medical Association
Infectious Disease Society of America
European Respiratory Society
American Society for Microbiology
Fellow, American College of Physicians
American College of International Physicians
Latinamerican Society of Infectious Diseases
Kentucky Medical Association
Kentucky Thoracic Society
Jefferson County Medical Society

MEDICAL LICENSURE

Kentucky License #25052
Washington, DC License #15806
Indiana License #01039060

UNIVERSITY OF LOUISVILLE COMMITTEES

1999-2000 Chairman: University of Louisville Pediatric Chair Review Committee
2002-2005 Member: University of Louisville Department of Medicine Promotion and Tenure Committee
2001-2003 Member: University of Louisville Faculty Forum
2002 Member: University of Louisville Search Committee for Chair of Human Studies
2003 Chairman: University of Louisville Dean of School of Medicine 5-year review Committee
2009-Present Member: Department of Medicine Promotion and Tenure Committee
2010-Present Member: Department of Medicine Faculty Compensation Committee

HOSPITAL COMMITTEES

1990-2012 Chairman: Veterans Affairs Medical Center Antibiotic Subcommittee
1990-Present Chairman: Veterans Affairs Medical Center Infection Control Committee
1990-1998 Member: Veterans Affairs Medical Center Pharmacy and Therapeutics Committee
1993-Present Chairman: University of Louisville Hospital Infection Control & Prevention Committee
1998-2013 Chairman: University of Louisville Hospital Antibiotic Subcommittee
1998-2014 Member: Clinical Research Foundation, Inc. Board of Directors
2000-2014 Chairman: Kindred Hospital Infection Control Committee

NATIONAL COMMITTEES

1999-2001 Member: American Thoracic Society Community-Acquired Pneumonia Guidelines Committee
2001-2005 Member: Food and Drug Administration advisory committee for anti-infective drugs
2006-2007 Member: US Department of Health and Human Services, National Institute of Health, National Institute of Allergy and Infectious Disease, Division of Extramural Activities, Scientific Review Board

HONORS

Updated June 2020

1987 -1988	Fellow Award for Excellence in Teaching University of Louisville, School of Medicine, Department of Medicine
1988-1989	Fellow Award for Excellence in Teaching University of Louisville, School of Medicine, Department of Medicine
1989	Elected as House Staff Member to Alpha Omega Alpha Honor Medical Society. Alpha of Kentucky Branch, University of Louisville School of Medicine
1994	Young Investigator Award University of Louisville
1995	School of Medicine Nomination in Recognition of Distinguished Service University of Louisville
1999	School of Medicine Nomination in Recognition of Distinguished Service University of Louisville
2013	Graduados Ilustres (Distinguished Graduates) National University of La Plata, School of Medicine
2013	Presidential Award (in recognition of outstanding contribution to research in respiratory infections and clinical management of pneumonia) European Respiratory Society

PRIMARY AREAS OF RESEARCH

1. Clinical and Translational Research in Pneumonia and Influenza
2. HIV Disease

REVIEWER FOR:

1. The New England Journal of Medicine
2. The Journal of Clinical Investigation
3. Southern Medical Journal
4. Circulation
5. Annals of Internal Medicine
6. American Journal of Obstetrics and Gynecology
7. Journal of Clinical Outcomes Management
8. American Journal of Surgery
9. European Respiratory Journal
10. Journal of Managed Care Pharmacy
11. Therapeutics and Clinical Risk Management
12. Joint Commission Journal on Quality and Safety
13. Chest
14. Clinical Infectious Diseases
15. Journal of Infection
16. Respiratory Research

RESEARCH PROJECTS

Research proposals identified as “*Investigator Initiated*” indicates that Dr. Ramirez developed the proposal. Research proposals identified as “*Industry Initiated*” indicates that a particular pharmaceutical company developed the proposal.

1. *Project Title:* “Activity of Fluoroquinolone antibiotics alone or in combination with Erythromycin or Rifampin against intracellular *Legionella pneumophila*”
Research Proposal: Investigator Initiated
Funding Source: Johnson Pharmaceutical Research Institute (\$8,500)
Role: Principal Investigator (1989)
2. *Project Title:* “Comparative Study of the Bactericidal Activity of Ampicillin/Sulbactam and Erythromycin Against Intracellular *Legionella pneumophila* in a Cell Culture Model”
Research Proposal: Investigator Initiated
Funding Source: Pfizer Pharmaceuticals (\$6,500)
Role: Principal Investigator (1989)
3. *Project Title:* “Activity of Cefixime against 500 Enterobacteriaceae Respiratory Isolates from Patients in intensive Care Units”
Research Proposal: Investigator Initiated
Funding Source: Lederle Laboratories (\$5,000)
Role: Principal Investigator (1989)
4. *Project Title:* “Activity of Temafloxacin for the Treatment of Patients with Community-Acquired Pneumonia Requiring Hospitalization.”
Research Proposal: Industry Initiated
Funding Source: Abbott Laboratories (\$35,000)
Role: Principal Investigator (1989-1991)
5. *Project Title:* “Development of a Drug Use Evaluation Program for Antimicrobial Agents”
Research Proposal: Investigator Initiated
Funding Source: Miles Laboratory (\$15,000)
Role: Principal Investigator (1990)
6. *Project Title:* “In Vitro Susceptibility Testing of 500 Respiratory Isolates From Patients at Risk of Hospital-Acquired Pneumonia”
Research Proposal: Investigator Initiated
Funding Source: SmithKline Beecham Pharmaceuticals (\$7,595)
Role: Principal Investigator (1990)
7. *Project Title:* “Prospective Bacteriological Study of Community-Acquired Pneumonia: Is *Legionella pneumophila* a significant pathogen?”
Research Proposal: Investigator Initiated
Funding Source: Hoechst-Roussel Pharmaceuticals, Inc. (\$3,000)
Role: Principal Investigator (1990-1991)
8. *Project Title:* “Bactericidal Activity of Imipenem compared to Erythromycin Against Intracellular *Legionella pneumophila*.”
Research Proposal: Investigator Initiated
Funding Source: Merck Sharp & Dohme, Inc. (\$1,200)
Role: Principal Investigator (1991)

9. *Project Title:* “Activity of Ampicillin/Sulbactam Against 100 Respiratory Tract Isolates From Patients With Community-Acquired Pneumonia.”
Research Proposal: Investigator Initiated
Funding Source: Pfizer Pharmaceuticals (\$2,500)
Role: Principal Investigator (1991)
10. *Project Title:* “Switch Therapy in Hospitalized Patients with Infections: Cost-Effectiveness Analysis.”
Research Proposal: Investigator Initiated
Funding Source: Lederle Laboratories (\$4,000)
Role: Principal Investigator (1991-1992)
11. *Project Title:* “Switch Therapy in Hospitalized Patients with Infections: Clinical and Social Outcomes.”
Research Proposal: Investigator Initiated
Funding Source: Miles Company (\$3,500)
Role: Principal Investigator 1991-1992)
12. *Project Title:* “Characterization of Legionella pneumophila Replication in Human Pulmonary and Umbilical Endothelial Cells.”
Research Proposal: Investigator Initiated
Funding Source: Abbott Laboratories (\$3,500)
Role: Co-Investigator (1992)
13. *Project Title:* “In Vitro Susceptibility Testing of 500 Isolates from Patients at Risk of Hospital-Acquired Pneumonia.”
Research Proposal: Investigator Initiated
Funding Source: SmithKline Beecham Pharmaceuticals (\$7,500)
Role: Principal Investigator (1992)
14. *Project Title:* “Cost-effectiveness of Legionella Urinary Antigen as Screening Test for Legionella Infections in Immunocompromised-compromised Patients.”
Research Proposal: Investigator Initiated
Funding Source: Alliant Community Trust (\$4,000)
Role: Principal Investigator (1992)
15. *Project Title:* “Comparative Trial of Ampicillin/Sulbactam versus Ceftriaxone for the initial empirical therapy of Community-Acquired Pneumonia.”
Research Proposal: Investigator Initiated
Funding Source: Hoffman-LaRoche, Inc. (\$15,000)
Role: Principal Investigator (1991-1992)
16. *Project Title:* “Switch Therapy with Oral Cefixime After a Short Course of IV Third Generation Cephalosporins for the Treatment of Patients with Community-Acquired Pneumonia”
Research Proposal: Investigator Initiated
Funding Source: Lederle Laboratories (\$120,000)
Role: Principal Investigator (1991-1993)
17. *Project Title:* “An Open-Label Multicenter Randomized Study Comparing IV Cefuroxime with IV Cefazolin as Empiric Treatment in Patients with Community-Acquired Pneumonia”
Research Proposal: Industry Initiated
Funding Source: Glaxo, Inc. (\$35,000)
Role: Principal Investigator (1991-1992)

18. *Project Title:* “Azithromycin Respiratory Infection Study”
Research Proposal: Investigator Initiated
Funding Source: Pfizer Labs Division (\$5,000)
Role: Principal Investigator (1991-1993)
19. *Project Title:* “Cefizoxime 1 Gram Every 12 Hours for the Treatment of Community-Acquired Pneumonia”
Research Proposal: Industry Initiated
Funding Source: Fujisawa, Inc. (\$30,000)
Role: Principal Investigator (1992-1993)
20. *Project Title:* “A Randomized, Comparative Trial of Aztreonam plus Cefazolin versus Ceftazidime in the Treatment of Nosocomial Pneumonia”
Research Proposal: Industry Initiated
Funding Source: Bristol-Myers Squibb (\$30,000)
Role: Principal Investigator (1992-1993)
21. *Project Title:* “Clinical Outcome of Patients with Community-Acquired Pneumonia Treated with a Regimen of Cefotaxime tid vs bid”
Research Proposal: Industry Initiated
Funding Source: Hoechst-Roussel Pharmaceuticals (\$92,400)
Role: Co-Investigator (1992-1993)
22. *Project Title:* “Diagnosis of *Mycoplasma pneumoniae* infections by the polymerases chain reaction.”
Research Proposal: Investigator Initiated
Funding Source: Alliant Community Trust Fund (\$21,260)
Role: Principal Investigator (1992)
23. *Project Title:* “Prospective Study on Intravenous Ciprofloxacin Monotherapy or Combination Therapy in the Treatment of Serious Infections”
Research Proposal: Industry Initiated
Funding Source: Miles Pharmaceutical (\$108,000)
Role: Principal Investigator (1993-1994)
24. *Project Title:* “Diagnosis and Prevalence of *Chlamydia pneumoniae* Infections”
Research Proposal: Investigator Initiated
Funding Source: Alliant Community Trust Fund, University of Louisville (\$44,784)
Role: Principal Investigator (1993)
25. *Project Title:* “Clinafloxacin versus Ceftazidime for the Treatment of Nosocomial Pneumonia”
Research Proposal: Industry Initiated
Funding Source: Parke Davis Laboratories (\$10,500)
Role: Principal Investigator (1993-1997)
26. *Project Title:* “Treatment of Patients with Community-Acquired Pneumonia Requiring Hospitalization with a Short Course of Intravenous Antibiotics and Switch Therapy to Oral Clarithromycin”
Research Proposal: Investigator Initiated
Funding Source: Abbott Laboratories (\$100,000)
Role: Principal Investigator (1993-1994)
27. *Project Title:* “Replication of Chlamydia species in cells associated with atherosclerosis”
Research Proposal: Investigator Initiated

- Funding Source:* Alliant Community Trust Fund, University of Louisville (\$9,667)
Role: Principal Investigator (1994)
28. *Project Title:* “Empiric Therapy of Febrile Neutropenic Cancer Patients with Clinafloxacin”
Research Proposal: Industry Initiated
Funding Source: Parke Davis Pharmaceuticals (\$14,000)
Role: Principal Investigator (1994-1996)
29. *Project Title:* “Incidence of Atypical Pathogens in Hospitalized Patients with Community-Acquired Pneumonia”
Research Proposal: Investigator Initiated
Funding Source: Parke Davis Laboratories (\$20,000)
Role: Principal Investigator (1994)
30. *Project Title:* “Secretion of chemoattractants and adhesion molecules by human endothelial cells infected with *Chlamydia pneumoniae*”
Research Proposal: Investigator Initiated
Funding Source: Jewish Hospital Heart and Lung Institute, UofL (\$7,346)
Role: Principal Investigator (1994)
31. *Project Title:* “Is *Chlamydia pneumoniae* present in the Coronary Atheroma of Patients with Coronary Artery Disease?”
Research Proposal: Investigator Initiated
Funding Source: Jewish Hospital Heart and Lung Institute, University of Louisville (\$6,530)
Role: Principal Investigator (1994)
32. *Project Title:* “Intravenous to Oral Azithromycin in Patients Hospitalized with Community-Acquired Pneumonia”
Research Proposal: Investigator Initiated
Funding Source: Pfizer Pharmaceuticals (\$21,800)
Role: Principal Investigator (1994-1995)
33. *Project Title:* “Interaction of *Chlamydia pneumoniae* with Cells Associated with Atherosclerosis.”
Research Proposal: Investigator Initiated
Funding Source: American Heart Association (\$29,720)
Role: Co-Investigator (1994)
34. *Project Title:* “Pharmacoeconomic Evaluation of a Critical Pathway for the Management of Patients with Community-Acquired Pneumonia”
Research Proposal: Investigator Initiated
Funding Source: SmithKline Beecham Pharmaceuticals (\$173,000)
Role: Principal Investigator (1995-1997)
35. *Project Title:* “Presence of *Chlamydia pneumoniae* in the Coronary Atheroma of Patients with Coronary Artery Disease”
Research Proposal: Investigator Initiated
Funding Source: University of Louisville (\$19,600)
Role: Co-Investigator (1995)
36. *Project Title:* “Ciprofloxacin Monotherapy/Combination Therapy for Treatment of Patients with Severe Sepsis”
Research Proposal: Industry Initiated
Funding Source: Miles Pharmaceuticals (\$29,200)

- Role:* Principal Investigator (1996-1997)
37. *Project Title:* “Filgrastim vs Placebo in Combination with Standard Antibiotic Therapy in the Treatment of Patients with Multi-lobar Pneumonia”
- Research Proposal:* Industry Initiated
- Funding Source:* Amgen (\$9,000)
- Role:* Principal Investigator (1996-1999)
38. *Project Title:* “Prospective, Non-Blinded, Randomized, Multi-Center Clinical Trial of the Efficacy, Safety, and Economic Impact of Empiric Ciprofloxacin (IV to PO) in Combination with Other Antibacterial Agents Compared with a Standard, Empiric, Intravenous Combination with Other Antibiotic Regimens for the Treatment of Patients with Pneumonia”
- Research Proposal:* Industry Initiated
- Funding Source:* Bayer Pharmaceuticals (\$76,440)
- Role:* Principal Investigator (1996-1998)
39. *Project Title:* “Clinafloxacin vs. Piperacillin-Tazobactam in the Treatment of Complicated Skin and Soft Tissue Infections”
- Research Proposal:* Industry Initiated
- Funding Source:* Parke-Davis (\$4,000)
- Role:* Principal Investigator (1996-1997)
40. *Project Title:* “Sparfloxacin in the Treatment of Community-Acquired Pneumonia in the Outpatient Setting”
- Research Proposal:* Industry Initiated
- Funding Source:* Concepts in Pharmaceutical Research (\$23,800)
- Role:* Principal Investigator (1996-1997)
41. *Project Title:* “Clinafloxacin vs Ceftriaxone in the Treatment of Hospitalized Patients with Community-Acquired Pneumonia”.
- Research Proposal:* Industry Initiated
- Funding Source:* Parke Davis Pharmaceuticals (\$153,000)
- Role:* Principal Investigator (1996-1998)
42. *Project Title:* “Switch Therapy to Oral Cefuroxime Axetil after a Short Course of IV Cefuroxime for the Treatment of Hospitalized Patients with Community-Acquired Pneumonia”.
- Research Proposal:* Investigator Initiated
- Funding Source:* GlaxoWellcome Pharmaceuticals (\$85,500)
- Role:* Principal Investigator (1996-1998)
43. *Project Title:* “L-749,345 vs. Ceftriaxone in the Treatment of Serious, Uncomplicated Lower Respiratory Tract Infections of Mild to Moderate Severity in Adults.”
- Research Proposal:* Industry Initiated
- Funding Source:* Merck Pharmaceuticals (\$5,975)
- Role:* Principal Investigator (1996-1997)
44. *Project Title:* “A Randomized, Double-Blind, Multi-Center, Comparative Study of Oral Gatifloxacin vs Trovafloxacin in the Treatment of Community-Acquired Pneumonia. AI420-067-012”
- Research Proposal:* Industry Initiated
- Funding Source:* Bristol-Myers Squibb (\$9,550)
- Role:* Principal Investigator (1996-1997)

45. *Project Title:* “Clinafloxacin in the Treatment of Endocarditis 960-017-17/96335”
Research Proposal: Industry Initiated
Funding Source: Parke Davis Pharmaceuticals (\$4,000)
Role: Principal Investigator (1997-1998)
46. *Project Title:* “Lamsil/Aspergillosis Study SFS 203-57”
Research Proposal: Industry Initiated
Funding Source: Novartis Pharmaceuticals (\$1,858)
Role: Principal Investigator (1997-1998)
47. *Project Title:* “Treatment of Nosocomial Pneumonia: Meropenem versus Imipenem”
Research Proposal: Industry Initiated
Funding Source: Zeneca Pharmaceuticals (\$29,802)
Role: Principal Investigator (1998-2000)
48. *Project Title:* “Community-Acquired Pneumonia study number 3591US/0022:0055”
Research Proposal: Industry Initiated
Funding Source: AstraZeneca Pharmaceuticals (\$40,087)
Role: Principal Investigator (1998-2000)
49. *Project Title:* “An Open-Label, Multicenter, Non-Comparative Phase II/III Study of Oral Gatifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia”
Research Proposal: Industry Initiated
Funding Source: Bristol-Myers Squibb Pharmaceuticals (\$8,542)
Role: Principal Investigator (1998-1999)
50. *Project Title:* “Prospective, Randomized, Double-Blind Comparison of the Safety and Efficacy of Oral Bay 12-8039 400mg QD versus Oral Cephalexin 500mg TID for the Treatment of Patients with Mild to Moderate Acute Uncomplicated Skin and Superficial Skin Structure Infection”
Research Proposal: Industry Initiated
Funding Source: Bayer Pharmaceuticals (\$2,000)
Role: Principal Investigator (1998-1999)
51. *Project Title:* “MK-0826 vs Ceftriaxone sodium in the Treatment of Serious CAP in Adults”
Research Proposal: Industry Initiated
Funding Source: Merck Pharmaceuticals (\$7,560)
Role: Principal Investigator (1998-1999)
52. *Project Title:* “In vitro comparison on the activity of Linezolid and Erythromycin against intracellular Legionella spp. using the human monocyte cell line RL-60”
Research Proposal: Investigator Initiated
Funding Source: Pharmacia & Upjohn Pharmaceuticals (\$9,471)
Role: Principal Investigator (1998-2000)
53. *Project Title:* “TAP 9801-protocol #CEF-97-009”
Research Proposal: Industry Initiated
Funding Source: Tap Holdings, Inc. (\$14,069)
Role: Principal Investigator (1998-1999)
54. *Project Title:* “Serious CAP. Protocol CAPSS-018”
Research Proposal: Industry Initiated

- Funding Source:* Ortho-McNeil Pharmaceuticals (\$8,128)
Role: Principal Investigator (1998-1999)
55. *Project Title:* “Gatifloxacin versus Clarithromycin Outpatient CAP Study “
Research Proposal: Industry Initiated
Funding Source: Bristol-Myers Squibb Pharmaceuticals (\$15,000)
Role: Principal Investigator (1999)
56. *Project Title:* “A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of IV Daptomycin with that of Vancomycin in a Semi-Synthetic Penicillin in the Treatment of Bacteremic Infections Due to Gram-Positive Bacteria. Protocol DAP-BAC-9803”
Research Proposal: Industry Initiated
Funding Source: Advanced Biologics (\$17,750)
Role: Principal Investigator (1999-2001)
57. *Project Title:* “A Randomized, Double-Blind, Multicenter, Comparative Study of Gatifloxacin versus Azithromycin in the Treatment of Acute Exacerbation of Chronic Bronchitis AI420-065-024”
Research Proposal: Industry Initiated
Funding Source: Bristol-Myers Squibb Pharmaceuticals (\$6,998)
Role: Principal Investigator (1999-2000)
58. *Project Title:* “Outpatient CAP Study AI420-067”
Research Proposal: Industry Initiated
Funding Source: Bristol-Myers Squibb Pharmaceuticals (\$3,500)
Role: Principal Investigator (1999-2000)
59. *Project Title:* “Prospective Clinical Trial of Intravenous Ceftriaxone plus Oral Clarithromycin versus IV Levofloxacin plus oral placebo for Initial Empiric Therapy of Hospitalized patients with Community-Acquired Pneumonia”
Research Proposal: Industry Initiated
Funding Source: Abbott Laboratories (\$143,950)
Role: Principal Investigator (1999-2002)
60. *Project Title:* “A Randomized, Double-Blind, Multi-Center, comparative Phase III Study of Oral BMS-284756 vs Oral Clarithromycin in the Treatment of Community-Acquired Pneumonia AI464-029”
Research Proposal: Industry Initiated
Funding Source: Bristol-Myers Squibb (\$1,950)
Role: Principal Investigator (2000-2001)
61. *Project Title:* “Community-Acquired Pneumonia Organization (CAPO). An international organization to foster research collaboration in CAP”
Research Proposal: Investigator Initiated
Funding Source: Bristol-Myers Squibb, Pfizer, Abbott, Ortho-McNeil, GlaxoSmithKline (\$200,000)
Role: Principal Investigator (2000-present)
62. *Project Title:* “Proteomic Analysis of Persistent Chlamydia Pneumoniae”
Research Proposal: Investigator Initiated
Funding Source: National Institutes of Health, National Heart, Lung, and Blood Institute (\$750,000)
Role: Co-Investigator (2001-2004)

63. *Project Title:* “A Randomized, Double-blind, Double-dummy, Phase III, Comparative Study of Cidecin (Daptomycin) and Zyvox (Linezolid) in the Treatment of Hospitalized Adults with Suspected Vancomycin-Resistant Enterococcal Infections. DAP-VRE-00-07”
Research Proposal: Industry Initiated
Funding Source: Cubist Pharmaceuticals (\$11,000)
Role: Principal Investigator (2002-2003)
64. *Project Title:* “The Role of Pneumococcal Urinary Antigen Testing in the Treatment of Patient with Community-Acquired Pneumonia (SpUA in CAP)”
Research Proposal: Industry Initiated
Funding Source: Binax (\$5,000)
Role: Principal Investigator (2003)
65. *Project Title:* “A Phase 3, Multicenter, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy in the Treatment of Subjects with Infective Endocarditis or Bacteremia Due to Staphylococcus aureus. Protocol DAP-IE-01-02”
Research Proposal: Industry Initiated
Funding Source: Cubist Pharmaceuticals (\$11,000)
Role: Principal Investigator (2004-2005)
66. *Project Title:* “Prospective, International, Randomized Clinical Trial to Define what Empiric Antibiotic Regimen (Monotherapy with Moxifloxacin versus Combination Therapy with Ceftriaxone or Cefotaxime plus Clarithromycin, Azithromycin, or Erythromycin) is Associated with Better Outcomes in Hospitalized Patients with Community-Acquired Pneumonia. Protocol CAPO202”
Research Proposal: Industry Initiated
Funding Source: Schering Plough (\$393,960)
Role: Principal Investigator (2004-2007)
67. *Project Title:* "A Randomized, Double-Blind Study of GT267-004 versus Vancomycin, and GT267-004 versus Metronidazole, in Patients with C. difficile-Associated Diarrhea"
Research Proposal: Industry Initiated
Funding Source: Genzyme (\$6,000)
Role: Sub-Investigator (2005-2007)
68. *Project Title:* "A Phase 3 Randomized, Double-Blind Study of Ceftobiprole Medocaril versus Linezolid plus Ceftazidime in the Treatment of Nosocomial Pneumonia"
Research Proposal: Industry Initiated
Funding Source: Johnson & Johnson (\$10,000)
Role: Sub-Investigator (2006-2008)
69. *Project Title:* “Improving Medicine through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT HAP). Multicenter, Retrospective, Observational Study to Evaluate Current Management of Patients with Hospital-Acquired Pneumonia”
Research Proposal: Investigator Initiated
Funding Source: Pfizer (\$667,000)
Role: Principal Investigator (2006-present)

70. *Project Title:* "Retrospective, Observational Study to Evaluate the Correlation of Inflammatory Markers with Clinical Outcomes in Patients with Osteomyelitis"
Research Proposal: Investigator Initiated
Funding Source: Unfunded
Role: Co-Investigator (2008-present)
71. *Project Title:* "Influence of Vancomycin MICs and SCCmec type on the Clinical Outcomes of Patients with Methicillin Resistant *Staphylococcus aureus* Osteomyelitis"
Research Proposal: Investigator Initiated
Funding Source: Cubist Pharmaceuticals (\$29,880)
Role: Principal Investigator (2008-present)
72. *Project Title:* "Severe Influenza Pneumonia Surveillance (SIPS) Network"
Research Proposal: Investigator Initiated
Funding Source: The National Institute for Hometown Security (Somerset, KY) (\$582,936)
Role: Principal Investigator (2008-2012)
73. *Project Title:* "Linezolid in the Treatment of Subjects with Nosocomial Pneumonia proven to be Methicillin-Resistant *Staphylococcus aureus*"
Research Proposal: Industry Initiated
Funding Source: Pfizer Pharmaceuticals (\$208,532)
Role: Principal Investigator (2008-2010)
74. *Project Title:* "Prospective Observational Study of Nosocomial *Clostridium difficile* Toxin Antibody Concentrations, Incidence and recurrence"
Research Proposal: Industry Initiated
Funding Source: Merck Pharmaceuticals (\$49,782)
Role: Principal Investigator (2009-2011)
75. *Project Title:* "Anti-Influenza Therapy in Hospitalized Patients with Community-Acquired Pneumonia"
Research Proposal: Investigator Initiated
Funding Source: Centers for Diseases Control and Prevention (\$1,649,379)
Role: Principal Investigator (2010-present)
76. *Project Title:* "Ryan White HIV/AIDS Grant" (Part C & Part D)
Research Proposal: Investigator Initiated
Funding Source: Health Resources and Services Administration, HIV/AIDS Bureau (\$928,627)
Role: Principal Investigator (2009-2011)
77. *Project Title:* "Ryan White HIV/AIDS Grant" (Part C & Part D)
Research Proposal: Investigator Initiated
Funding Source: Health Resources and Services Administration, HIV/AIDS Bureau (\$928,627)
Role: Co-Investigator (2012-2014)
78. *Project Title:* "The Role of Alcohol in HIV Therapy Hepatotoxicity"
Research Proposal: Investigator Initiated
Funding Source: National Institutes of Health (R01) (\$1,850,000)
Role: Co-Investigator (2009-2013)
79. *Project Title:* "Microbiology Testing With the Aim of Directed Antimicrobial Therapy for Community-Acquired Pneumonia/DMID Protocol 10- 0061"

- Research Proposal:* Investigator Initiated
Funding Source: NIAID-Division of Microbiology and Infectious Diseases (\$2,727,706)
Role: Site Principal Investigator (2012-2013)
80. *Project Title:* “The Impact of Oxidative Stress on HIV-induced Lung Disease”
Research Proposal: Investigator Initiated
Funding Source: National Institutes for Health (NIH) (\$870,395)
Role: Principal Investigator (2013-2018)
81. *Project Title:* “Population-Based Study to Define the Clinical & Economic Burden of Pneumococcal Pneumonia in Hospitalized Adults in Jefferson County, Kentucky”
Research Proposal: Investigator Initiated
Funding Source: Pfizer Pharmaceuticals (\$350,880)
Role: Principal Investigator (2014-2015)
82. *Project Title:* “Streptococcus Pneumoniae Serotypes in Adults 18 Years and older with Radiographically-Confirmed Community-Acquired Pneumonia Kentucky”
Research Proposal: Industry Initiated
Funding Source: Pfizer Pharmaceuticals (\$9,500,000)
Role: Principal Investigator (2014-2018)
83. *Project Title:* “A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC”
Research Proposal: Industry Initiated
Funding Source: Gilead Sciences, Inc. (\$404,168)
Role: Principal Investigator (2015-2020)
84. *Project Title:* “The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ Injury. Sub-study of: SAM Deficiency Mediated Epigenetic Mechanisms in Alcohol Induced Immunosuppression.”
Research Proposal: Investigator Initiated
Funding Source: National Institutes of Health (\$1,201,620)
Role: Co-Investigator (2015-2021)
85. *Project Title:* “A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed”
Research Proposal: Industry Initiated
Funding Source: Gilead Sciences, Inc. (\$175,979)
Role: Principal Investigator (2016-2021)
86. *Project Title:* “An Open-Label, Non-Randomized Single-Arm Staphylococcal Bone or Joint Infections in Subjects for whom Chronic Antibiotic Suppressive Therapy is Indicated”
Research Proposal: Industry Initiated
Funding Source: Covance (\$177,000)
Role: Principal Investigator (2016-2021)
87. *Project Title:* “A Phase-3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus

- Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment –Naïve Adults”
- Research Proposal:* Industry Initiated
Funding Source: Gilead Sciences, Inc. (\$230,090)
Role: Principal Investigator (2016-2021)
88. *Project Title:* “A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults”
- Research Proposal:* Industry Initiated
Funding Source: Gilead Sciences, Inc. (\$142,456)
Role: Principal Investigator (2016-2021)
89. *Project Title:* “Clinical & Economic Burden in Hospitalized Adults with Pneumococcal Pneumonia in Louisville, Kentucky: Incidence Study (HAPPI)”
- Research Proposal:* Investigator Initiated
Funding Source: Pfizer Pharmaceuticals (\$3,615,217)
Role: Principal Investigator (2016-2018)
90. *Project Title:* “A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed”
- Research Proposal:* Industry Initiated
Funding Source: Gilead Sciences, Inc. (\$250,000)
Role: Principal Investigator (2017-2022)
91. *Project Title:* “Expanded Access IND Program (EAP) to Provide Stamaril Vaccine to Persons in the United States for Vaccination Against Yellow Fever”
- Research Proposal:* Industry Initiated
Funding Source: Sanofi Pasteur (\$150,192)
Role: Principal Investigator (2017-2018)
92. *Project Title:* “Clinical and Translational Research in Pneumonia: Defining a Research Agenda for Today and Tomorrow”
- Research Proposal:* Investigator Initiated
Funding Source: National Institutes of Health (\$5,000)
Role: Principal Investigator (2017-2018)
93. *Project Title:* “Burden of Hospitalized Adults with Group B Streptococcal (*Streptococcus agalactiae*) Infections in Louisville, Kentucky (BASIL)”
- Research Proposal:* Industry Initiated
Funding Source: Pfizer Pharmaceuticals (\$250,000)
Role: Principal Investigator (2017-2018)
94. *Project Title:* “Role of Gut Microbial Dysbiosis and Aging on HIV-associated neurocognitive and brain dysfunction”
- Research Proposal:* Investigator Initiated
Funding Source: National Institutes of Health (\$779,748)
Role: Co-Investigator (2018-2023)

95. *Project Title:* “Diarrhea Burden in Adults in the United States attributable to Clostridioides Difficile: An Active Surveillance Study”
Research Proposal: Industry Initiated
Funding Source: Pfizer Pharmaceuticals (\$6,500,000)
Role: Principal Investigator (2019-2020)
96. *Project Title:* “Serotype Distribution of Streptococcus Pneumonia in Hospitalized Adults \geq 18 Years of Age in the United States”
Research Proposal: Industry Initiated
Funding Source: Pfizer Pharmaceuticals (\$4,500,000)
Role: Principal Investigator (2019-2021)
97. *Project Title:* “Louisville Coronavirus Surveillance Program”
Research Proposal: Investigator Initiated
Funding Source: University of Louisville President’s Office (\$500,000)
Role: Principal Investigator (2020)
98. *Project Title:* “Defining the Burden of COVID-19 in the Kentuckiana Area: Incidence, Epidemiology & Clinical Outcomes of Patients with COVID-19”
Research Proposal: Investigator Initiated
Funding Source: Unfunded
Role: Principal Investigator (2020-2021)

PUBLICATIONS (Peer Review Journals)

1. Raff M, **Ramirez J**. Lower Respiratory Tract Infections: A Brief Review. *Infect Med*. 1991;8:45–8.
2. Summersgill JT, Powell LA, Buster BL, Miller RD, **Ramirez JA**. Killing of *Legionella pneumophila* by nitric oxide in γ -interferon-activated macrophages. *J Leukoc Biol*. 1992 Dec;52(6):625–9
<https://doi.org/10.1002/jlb.52.6.625> PMID:1464734
3. **Ramirez JA**, Summersgill JT, Miller RD, Meyers TL, Raff MJ. Bactericidal activity of imipenem compared to erythromycin against intracellular *Legionella pneumophila*. *Drugs Exp Clin Res*. 1992;18(10):407–10. PMID:1306151
4. **Ramirez J**, Raff M. Sepsis Syndrome-Recognition and Pathophysiology. *Complications in Surgery*. 1992 May;11(5):38–45.
5. **Ramirez J**, Burke J, Ritter B, Raff M. Determining When to Use Antiendotoxin Antibody HA-1A. *P T*. 1992;17:1165–79.
6. **Ramirez JA**, Anderson P, Herp S, Raff MJ. Increased rate of tuberculin skin test conversion among workers at a university hospital. *Infect Control Hosp Epidemiol*. 1992 Oct;13(10):579–81. <https://doi.org/10.2307/30148459> PMID:1334986
7. **Ramirez J**, Burke J, Ritter B. Drug Use Evaluation Program for Antimicrobial Agents: development and Implementation. *P T*. 1993;18:267–73.
8. **Ramirez J**, Raff M. Penicillin-Resistant *Streptococcus pneumoniae* in the United States: Clinical Implications for Therapy. *Infect Med*. 1993;10:24–9.
9. **Ramirez JA**, Summersgill JT, Miller RD, Meyers TL, Raff MJ. Comparative study of the bactericidal activity of ampicillin/sulbactam and erythromycin against intracellular *Legionella pneumophila*. *J Antimicrob Chemother*. 1993 Jul;32(1):93–9.
<https://doi.org/10.1093/jac/32.1.93> PMID:8226420
10. **Ramirez JA**. The choice of empirical antibiotic therapy for nosocomial pneumonia. *J Chemother*. 1994 Apr;6 Suppl 2:47–50 PMID:7799054
11. Ahkee S, Srinath L, Huang A, Raff MJ, **Ramirez JA**. Lemierre’s syndrome: postanginal sepsis due to anaerobic oropharyngeal infection. *Ann Otol Rhinol Laryngol*. 1994 Mar;103(3):208–10. <https://doi.org/10.1177/000348949410300307> PMID:8122837
12. Fekete T, Castellano M, **Ramirez J**, Siefkin A, Martin M, Redington JJ, North D, Krumpke P, Javaheri S, Jones R, Gagnon S. A randomised comparative trial of aztreonam plus cefazolin versus ceftazidime for the treatment of nosocomial pneumonia. *Drug Investig*. 1994 Mar;7(3):117–26.
<https://doi.org/10.1007/BF03258463>.
13. **Ramirez JA**. Advances in antibiotic use: switch therapy. *Curr Ther Res Clin Exp*. 1994 Jan;55:30–4.
[https://doi.org/10.1016/S0011-393X\(05\)80724-6](https://doi.org/10.1016/S0011-393X(05)80724-6).
14. **Ramirez JA**, Srinath L, Ahkee S, Huang AK, Raff MJ. HIV-negative “AIDS” in Kentucky: a case of idiopathic CD4+ lymphopenia and cryptococcal meningitis. *South Med J*. 1994 Jul;87(7):751–2. <https://doi.org/10.1097/00007611-199407000-00016> PMID:8023211
15. **Ramirez J**, Srinath L, Hayden J, Ahkee S, Raff M. Penicillin-Resistant *Streptococcus pneumoniae* in Louisville, Kentucky: Implications for the Pharmacy and Therapeutics Committee. *Pharmacy & Therapeutics* 19:857–65.
16. Ahkee S, Smith R, Ritter W, **Ramirez J**. Once Daily Dosing of Aminoglycosides in Severe Lower Respiratory Tract Infections. *P T*. 1995;20:226–34.

17. **Ramirez J.** Srinath L, Ahkee S, Huang A, Raff M. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. *Arch Intern Med.* 1995 Jun;155(12):1273-6. <https://doi.org/10.1001/archinte.1995.00430120050006> PMID:7778957
18. Ahkee S, **Ramirez J.** Approach to the Patient with Suspected Meningitis. *Infect Med.* 1995;12:89–89.
19. **Ramirez J.** Ahkee S, Huang A. Cost Savings of Oral Cefixime as Switch Therapy for Treatment of Community-Acquired Pneumonia. *Infect Med.* 1996;13:616–20.
20. Ritter B, Burke J. **Ramirez J.** Evolution of the Hospital Antibiotic Formulary at the Veterans Medical Center of Louisville. *P T.* 1996;20:270–7.
21. **Ramirez JA.** Switch therapy in community-acquired pneumonia. *Diagn Microbiol Infect Dis.* 1995 May-Jun;22(1-2):219–23. [https://doi.org/10.1016/0732-8893\(95\)00088-R](https://doi.org/10.1016/0732-8893(95)00088-R) PMID:7587043
22. Summersgill JT, Sahney NN, Gaydos CA, Quinn TC, **Ramirez JA.** Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha. *Infect Immun.* 1995 Jul;63(7):2801–3. PMID:7790105 PMCID:PMC173379
23. **Ramirez JA.** Switch therapy in adult patients with pneumonia. *Clin Pulm Med.* 1995 Nov;2(6):327–33. <https://doi.org/10.1097/00045413-199511000-00002>.
24. **Ramirez JA,** Ahkee S, Tolentino A, Miller RD, Summersgill JT. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. *Diagn Microbiol Infect Dis.* 1996 Jan;24(1):7–14. [https://doi.org/10.1016/0732-8893\(95\)00254-5](https://doi.org/10.1016/0732-8893(95)00254-5) PMID:8988757
25. Gaydos CA, Summersgill JT, Sahney NN, **Ramirez JA,** Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. *Infect Immun.* 1996 May;64(5):1614–20. PMID:8613369
26. Ahkee S, Barzallo M, **Ramirez J.** Empiric Antibiotic Therapy in Patients Without Documented Infections. *Infect Med.* 1996;13(9):800–2.
27. **Ramirez JA.** Antibiotic streamlining: development and justification of an antibiotic streamlining program. *Pharmacy practice management quarterly.* 1996 Oct;16(3):19-34. PMID:10166232
28. Burke JD, Ahkee S, Ritter GW, **Ramirez JA.** Development of an interdisciplinary antimicrobial team: elements for success. *Hosp Pharm.* 1996;31(4):361–6.
29. Ahkee S, **Ramirez J.** A case of concurrent Lyme meningitis with ehrlichiosis. *Scand J Infect Dis.* 1996;28(5):527-8. PMID:8953687 <https://doi.org/10.3109/00365549609037953>
30. **Ramirez J.** Switch Therapy: Development, Implementation, and Economics. *Am J Manag Care.* 1996;2:S17–25.
31. **Ramirez JA.** Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. *Ann Intern Med.* 1996 Dec;125(12):979–82. <https://doi.org/10.7326/0003-4819-125-12-199612150-00008> PMID:8967709
32. **Ramirez J.** Terapeutica secuencial en pacientes con pneumonia adquirida en la comunidad. *Farmacoeconomia* 1996 Num. VI:8-18.
33. **Ramirez J.** Ahkee S. Early switch from Intravenous Antibiotics to Oral Clarythromycin in the Treatment of Hospitalized Patients with Community-Acquired Pneumonia. *Infect Med.* 1997;14:318–23.

34. Ahkee S, Smith S, Newman D, Ritter W, Burke J, **Ramirez JA**. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-month prospective study. *Pharmacotherapy*. 1997 May-Jun;17(3):569–75. PMID:9165561
35. Ahkee S, Srinath L, **Ramirez J**. Community-acquired pneumonia in the elderly: association of mortality with lack of fever and leukocytosis. *South Med J*. 1997 Mar;90(3):296–8. <https://doi.org/10.1097/00007611-199703000-00006> PMID:9076300
36. Uyamadu N, Ahkee S, Carrico R, Tolentino A, Wojda B, **Ramirez J**. Reduction in tuberculin skin-test conversion rate after improved adherence to tuberculosis isolation. *Infect Control Hosp Epidemiol*. 1997 Aug;18(8):575-9. PMID:9276240 <https://doi.org/10.2307/30141269>
37. File TM Jr, Bartlett JG, Cassell GH, Gaydos CA, Grayston T, Hammerschlag MR, et al. **Ramirez JA**, Saikku P, Schachter J, Schumacher HR, Stamm WE, Stratton CW, Yu VL. The Importance of Chlamydia pneumoniae as a Pathogen: The 1996 Consensus Conference on Chlamydia pneumoniae Infections. *Infect Dis Clin Pract*. 1997;6 Supplement 2:S28–31. <https://doi.org/10.1097/00019048-199711002-00002>.
38. Pinar A, Ahkee S, Miller RD, **Ramirez JA**, Summersgill JT. Use of heteroduplex analysis to classify legionellae on the basis of 5S rRNA gene sequences. *J Clin Microbiol*. 1997 Jun;35(6):1609–11. PMID:9163496
39. **Ramirez JA**. Clinafloxacin in the Treatment of Hospitalised Patients with Serious Infections. *Clin Drug Investig*. 1998;15 Suppl 1:35–8. <https://doi.org/10.2165/00044011-199815001-00004>.
40. Molestina RE, Dean D, Miller RD, **Ramirez JA**, Summersgill JT. Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the omp1 gene and biological activity in human endothelial cells. *Infect Immun*. 1998 Apr;66(4):1370–6. PMID:9529055
41. Mehta SJ, Miller RD, **Ramirez JA**, Summersgill JT. Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: role of tryptophan catabolism. *J Infect Dis*. 1998 May;177(5):1326–31. <https://doi.org/10.1086/515287> PMID:9593020
42. **Ramirez JA**. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia. *Ann Pharmacother*. 1998 Jan;32(1):S22–6 <https://doi.org/10.1177/106002809803200106> PMID:9475836
43. Coxon PY, Summersgill JT, **Ramirez JA**, Miller RD. Signal transduction during Legionella pneumophila entry into human monocytes. *Infect Immun*. 1998 Jun;66(6):2905–13. PMID:9596766
44. Molestina RE, Miller RD, **Ramirez JA**, Summersgill JT. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. *Infect Immun*. 1999 Mar;67(3):1323–30. PMID:10024578
45. **Ramirez J**, Unowsky J, Talbot GH, Zhang H, Townsend L. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. *Clin Ther*. 1999 Jan;21(1):103–17. [https://doi.org/10.1016/S0149-2918\(00\)88271-5](https://doi.org/10.1016/S0149-2918(00)88271-5) PMID:10090428
46. **Ramirez JA**, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. *Arch Intern Med*. 1999 Nov;159(20):2449–54. <https://doi.org/10.1001/archinte.159.20.2449> PMID:10665893
47. Ramirez J. Penicillin-resistant pneumococci: new-generation fluoroquinolones and lower respiratory tract infections. *Hosp Med*. 1999 Jun.
48. **Ramirez JA**, Nguyen TH, Tellier G, Coppola G, Bettis RB, Dolmann A, St-Pierre C, Mayer H. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. *J Respir Dis*. 1999;20 Suppl 11:S40-8.

49. Summersgill JT, Molestina RE, Miller RD, **Ramirez JA**. Interactions of *Chlamydia pneumoniae* with human endothelial cells. *J Infect Dis*. 2000 Jun;181(s3 Suppl 3):S479–82. <https://doi.org/10.1086/315620> PMID:10839743
50. Plouffe J, Schwartz DB, Kolokathis A, Sherman BW, Arnow PM, Gezon JA, Suh B, Anzuetto A, Greenberg RN, Niederman M, Paladino JA, **Ramirez JA**, Inverso J, Knirsch CA; The Azithromycin Intravenous Clinical Trials Group. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. *Antimicrob Agents Chemother*. 2000 Jul 1;44(7):1796-802. <https://doi.org/10.1128/AAC.44.7.1796-1802.2000> PMID:10858333
51. Molestina RE, Miller RD, Lentsch AB, **Ramirez JA**, Summersgill JT. Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by *Chlamydia pneumoniae* in human endothelial cells. *Infect Immun*. 2000 Jul;68(7):4282–8 <https://doi.org/10.1128/IAI.68.7.4282-4288.2000> PMID:10858246
52. **Ramirez JA**. Community-Acquired Pneumonia in Elderly Patients and Length of Hospitalization—Reply. *Archives of Internal Medicine*. 2000 Sep 25;160(17):2678-1679.
53. Pantoja LG, Miller RD, **Ramirez JA**, Molestina RE, Summersgill JT. Inhibition of *Chlamydia pneumoniae* replication in human aortic smooth muscle cells by gamma interferon-induced indoleamine 2, 3-dioxygenase activity. *Infect Immun*. 2000 Nov;68(11):6478–81 <https://doi.org/10.1128/IAI.68.11.6478-6481.2000> PMID:11035763
54. **Ramirez JA**, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired *Streptococcus pneumoniae* pneumonia. *Arch Intern Med*. 2001 Mar;161(6):848–50 <https://doi.org/10.1001/archinte.161.6.848> PMID:11268227
55. Sahney NN, Summersgill JT, **Ramirez JA**, Miller RD. Inhibition of oxidative burst and chemotaxis in human phagocytes by *Legionella pneumophila* zinc metalloprotease. *J Med Microbiol*. 2001 Jun;50(6):517–25. <https://doi.org/10.1099/0022-1317-50-6-517> PMID:11393289
56. Pantoja LG, Miller RD, **Ramirez JA**, Molestina RE, Summersgill JT. Characterization of *Chlamydia pneumoniae* persistence in HEP-2 cells treated with gamma interferon. *Infect Immun*. 2001 Dec;69(12):7927–32. <https://doi.org/10.1128/IAI.69.12.7927-7932.2001> PMID:11705979
57. Niederman MS, Mandell LA, Anzuetto A, Bass JB, Broughton WA, Campbell GD, Campbell, Douglas G, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, **Ramirez J**, Sarosi GA, Torres A, Wilson R, Yu, VL; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. *Am J Respir Crit Care Med*. 2001 Jun;163(7):1730–54. <https://doi.org/10.1164/ajrccm.163.7.at1010> PMID:11401897
58. Uriarte SM, Molestina RE, Miller RD, Bernabo J, Farinati A, Eiguchi K, **Ramirez JA**, Summersgill JT. Effect of macrolide antibiotics on human endothelial cells activated by *Chlamydia pneumoniae* infection and tumor necrosis factor- α . *Journal of Infectious Diseases*. 2002 Jun 1;185(11):1631-6 <https://doi.org/10.1086/340575> PMID:12023769
59. Pinar A, **Ramirez JA**, Schindler LL, Miller RD, Summersgill JT. The use of heteroduplex analysis of polymerase chain reaction products to support the possible transmission of *Legionella pneumophila* from a malfunctioning automobile air conditioner. *Infect Control Hosp Epidemiol*. 2002 Mar;23(3):145–7 <https://doi.org/10.1086/502025> PMID:11918120
60. Molestina RE, Klein JB, Miller RD, Pierce WH, **Ramirez JA**, Summersgill JT. Proteomic analysis of differentially expressed *Chlamydia pneumoniae* genes during persistent infection of HEP-2 cells. *Infect Immun*. 2002 Jun;70(6):2976–81 <https://doi.org/10.1128/IAI.70.6.2976-2981.2002> PMID:12010987

61. **Ramirez JA.** Guidelines for community-acquired pneumonia in the US and Canada: a practical approach to antibiotic selection. *Compr Ther.* 2002;28(3):201–7. <https://doi.org/10.1007/s12019-002-0029-5> PMID:12360632
62. Hammerschlag MR, Reznik T, Roblin PM, **Ramirez J**, Summersgill J, Bukofzer S. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to *Chlamydia pneumoniae*. *J Antimicrob Chemother.* 2003 Apr;51(4):1025–8. <https://doi.org/10.1093/jac/dkg154> PMID:12654764
63. **Ramirez JA.** Guidelines for Community-Acquired Pneumonia Within Disease Management Programs. *Dis Manag Health Outcomes.* 2003 Jan;11(1):33–43. <https://doi.org/10.2165/00115677-200311010-00005>.
64. Ferro TJ, Schwartz DB. **Ramirez JA.** Community-Acquired Pneumonia: Recommendations for Implementing Clinical Practice Guidelines in the Veterans Affairs Healthcare System. *Clin Pulm Med.* 2003;9 6S:S1–9.
65. **Ramirez JA.** Community-acquired pneumonia in adults. *Prim Care.* 2003 Mar;30(1):155–71. [https://doi.org/10.1016/S0095-4543\(02\)00076-3](https://doi.org/10.1016/S0095-4543(02)00076-3) PMID:12825254
66. Arnold FW, **Ramirez JA**, McDonald LC, Xia EL. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. *Chest.* 2003 Jul;124(1):121–4. <https://doi.org/10.1378/chest.124.1.121> PMID:12853513
67. Arnold FW, McDonald LC, Newman D, Smith RS, **Ramirez JA**, Ritter GW. Improving antimicrobial use: longitudinal assessment of an antimicrobial team including a clinical pharmacist. *J Manag Care Pharm.* 2004 Mar-Apr;10(2):152–8 <https://doi.org/10.18553/jmcp.2004.10.2.152> PMID:15032564
68. File TM Jr, Garau J, Blasi F, Chidiac C, Klugman K, Lode H, Lonks JR, Mandell L, **Ramirez J**, Yu V. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. *Chest.* 2004 May;125(5):1888–901 <https://doi.org/10.1378/chest.125.5.1888> PMID:15136404
69. Arnold FW, McDonald LC, Mangino PD, Dobbs SL. **Ramirez JA.** The Appropriateness of Hospital Antimicrobial use Between Medical and Surgical Specialties. *Formulary-Cleveland.* 2004 Jun 1;39:304–8.
70. ALAT Work Group (Grupo de trabajo de la Asociación Latinoamericana del Tórax). Update to the Latin American Thoracic Society (ALAT) Recommendations on Infectious Exacerbation of COPD. *Arch Bronconeumol.* 2004 Jul;40(7):315–25. [https://doi.org/10.1016/S1579-2129\(06\)60309-1](https://doi.org/10.1016/S1579-2129(06)60309-1) PMID:15225518
71. Grupo de trabajo de la Asociación Latinoamericana del Tórax (ALAT). [Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia]. *Arch Bronconeumol.* 2004 Aug;40(8):364–74 [https://doi.org/10.1016/S1579-2129\(06\)60322-4](https://doi.org/10.1016/S1579-2129(06)60322-4) PMID:15274866
72. Uriarte SM, Molestina RE, Miller RD, Bernabo J, Farinati A, Eiguchi K, **Ramirez JA**, Summersgill JT. Effects of fluoroquinolones on the migration of human phagocytes through *Chlamydia pneumoniae*-infected and tumor necrosis factor alpha-stimulated endothelial cells. *Antimicrobial agents and chemotherapy.* 2004 Jul 1;48(7):2538–43 <https://doi.org/10.1128/AAC.48.7.2538-2543.2004> PMID:15215106
73. Yu VL, **Ramirez J**, Roig J, Sabria M. Legionnaires disease and the updated IDSA guidelines for community-acquired pneumonia. *Clin Infect Dis.* 2004 Dec;39(11):1734–7. <https://doi.org/10.1086/425921> PMID:15578385

74. Christensen D, Feldman C, Rossi P, Marrie T, Blasi F, Luna C, Fernandez P, Porras J, Martinez J, Weiss K, Levy G, Lode H, Gross P, File T, **Ramirez J**, and the Community-Acquired Pneumonia Organization (CAPO) Investigators. "The Presence of HIV Infection Does Not Influence Clinical Outcomes in Hospitalized Patients with Bacterial Community-Acquired Pneumonia: Results from the CAPO International Cohort Study". *Clinical Infectious Diseases* 15, 2005; 41:554-6.
75. **Ramirez J**. Multicenter, multinational observational studies: a new approach to studying community-acquired pneumonia. *Respir Care Clin N Am*. 2005 Mar;11(1):35–44. <https://doi.org/10.1016/j.rcc.2004.10.011> PMID:15763220
76. **Ramirez JA**; Community-Acquired Pneumonia Organization Investigators. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. *Semin Respir Crit Care Med*. 2005 Dec;26(6):543–52. <https://doi.org/10.1055/s-2005-925521> PMID:16388426
77. Ramirez JA. Controlling multiple-drug-resistant organisms at the hospital level. *Expert Opin Pharmacother*. 2006 Aug;7(11):1449–55. <https://doi.org/10.1517/14656566.7.11.1449> PMID:16859428
78. Toala I, Christensen D, Huang A, **Ramirez J**. A Severe Community-Acquired Pneumonia Caused by Dual-Culprit Pathogens, *Streptococcus pneumoniae* and *Klebsiella pneumoniae*. *Infect Dis Clin Pract*. 2006;14:52–54 <https://doi.org/10.1097/01.idc.0000179880.75184.c3>
79. Arnold FW, McDonald LC, Smith RS, Newman D, **Ramirez JA**. Improving antimicrobial use in the hospital setting by providing usage feedback to prescribing physicians. *Infect Control Hosp Epidemiol*. 2006 Apr;27(4):378–82 <https://doi.org/10.1086/503336> PMID:16622816
80. Borel N, Mukhopadhyay S, Kaiser C, Sullivan ED, Miller RD, Timms P, Summersgill JT, **Ramirez JA**, Pospischil A. Tissue MicroArray (TMA) analysis of normal and persistent *Chlamydia pneumoniae* infection. *BMC Infect Dis*. 2006 Oct 19;6(1):152. <https://doi.org/10.1186/1471-2334-6-152> PMID:17052347
81. De la Cruz R, Toala I, Nakamatsu R, Huang A. **Ramirez J**. Invasive Pulmonary Aspergillosis in a Persistent Neutropenic Host Successfully Treated with Voriconazole and Caspofungin Combination Therapy. *Infect Dis Clin Pract*. 2006;14:52–4.
82. Arnold F, LaJoie A, Marrie T, Rossi P, Blasi F, Luna C, Fernandez P, Porras J, Weiss K, Feldman C, Rodriguez E, Levy G, Arteta F, Roig J, Rello J, **Ramirez J**, Community-Acquired Pneumonia Organization. The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia. *The International Journal of Tuberculosis and Lung Disease*. 2006 Jul 1;10(7):739-43. PMID:16848334
83. Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, Blasi F, Fernandez P, File Jr TM, Rello J, Menendez R, Marzoratti L, Luna CM, **Ramirez JA**, Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. *Am J Respir Crit Care Med*. 2007 May;175(10):1086–93. <https://doi.org/10.1164/rccm.200603-350OC> PMID:17332485
84. **Ramirez JA**. Fostering international multicenter collaborative research: the CAPO Project. *Int J Tuberc Lung Dis*. 2007 Oct;11(10):1062–5. PMID:17945061
85. Christensen D, Luna CM, Martínez J, Rodriguez E, Marzoratti L, Gonzalez J, Videla AJ, De Vedia L, Corral J, Benchetrit G, Rodriguez M, Victorio C, Lopardo G, Peyrani P, **Ramirez J**. Cumplimiento con las guías nacionales en pacientes hospitalizados con neumonía adquirida en la comunidad: Resultados del estudio capo en Argentina. [Adherence with national guidelines in hospitalized patients with community-acquired pneumonia. Results of CAPO study in Argentina]. *Medicina (B Aires)*. 2007;67(6 Pt 2):709–13. PMID:18422063

86. Borel N, Summersgill JT, Mukhopadhyay S, Miller RD, **Ramirez JA**, Pospischil A. Evidence for persistent **Chlamydia pneumoniae** infection of human coronary atheromas. *Atherosclerosis*. 2008 Jul;199(1):154–61 <https://doi.org/10.1016/j.atherosclerosis.2007.09.026> PMID:18028932
87. Carrico R, **Ramirez J**. A process for analysis of sentinel events due to health care-associated infection. *Am J Infect Control*. 2007 Oct;35(8):501–7 <https://doi.org/10.1016/j.ajic.2006.12.008> PMID:17936140
88. Bordon J, Peyrani P, Brock GN, Blasi F, Rello J, File T, **Ramirez J**, CAPO Study Group. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. *Chest*. 2008 Mar;133(3):618–24. <https://doi.org/10.1378/chest.07-1322> PMID:18198264
89. Peyrani P, **Ramirez J**. Fluoroquinolones in hospitalized patients with CAP: an evidence-based review. *Infect Med*. 2008; 25(4).
90. **Ramirez J**, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, Moffett B, Gordon J, Blasi F, Bordon J. Acute Myocardial Infarction in Hospitalized Patients with Community-Acquired Pneumonia. *Clinical infectious diseases*. 2008 Jul 15;47(2):182-7.
91. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, **Ramirez JA**, Christiansen KJ, Waterer GW, Pierce RJ, Australian Community-Acquired Pneumonia Study Collaboration. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. *Clin Infect Dis*. 2008 Aug;47(3):375–84 <https://doi.org/10.1086/589754> PMID:18558884
92. De la Cruz R, Toala I, Nakamatsu R, Huang A, **Ramirez J**. Invasive pulmonary aspergillosis in a patient with persistent neutropenia. *Infect Med*. 2007;24(10):455–7.
93. Aliberti S, Amir A, Peyrani P, Mirsaeidi M, Allen M, Moffett BK, Myers J, Shaib F, Cirino M, Bordon J, Blasi F, **Ramirez JA**. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. *Chest*. 2008 Nov 1;134(5):955–62 <https://doi.org/10.1378/chest.08-0334> PMID:18583514
94. Aliberti S, Myers JA, Peyrani P, Blasi F, Menendez R, Rossi P, Cosentini R, Lopardo G, de Vedia L, **Ramirez JA**. The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia. *Eur Respir J*. 2009 Jan;33(1):142–7 <https://doi.org/10.1183/09031936.00167707> PMID:18829671
95. Malinis M, Myers J, Bordon J, Peyrani P, Kapoor R, Nakamatzu R, Lopardo G, Torres A, Feldman C, Allen M, Arnold F, **Ramirez J**. Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia. *Int J Infect Dis*. 2010 Jan;14(1):e22–7 <https://doi.org/10.1016/j.ijid.2009.03.001> PMID:19586789
96. Mirsaeidi M, Peyrani P, **Ramirez JA**, and the Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (MMPACT-HAP) Investigators. Predicting Mortality in Patients with Ventilator-Associated Pneumonia: The Apache II Score versus the New IBMP-10 Score. *Clin Infect Dis*. 2009 Jul;49(1):72–7 <https://doi.org/10.1086/599349> PMID:19480582
97. Aliberti S, Brock GN, Peyrani P, Blasi F, **Ramirez JA**; Community-Acquired Pneumonia Organization. The pneumonia severity index and the CRB-65 in cancer patients with community-acquired pneumonia. *Int J Tuberc Lung Dis*. 2009 Dec;13(12):1550–6. PMID:19919775
98. Arnold FW, LaJoie AS, Brock GN, Peyrani P, Rello J, Menéndez R, Lopardo G, Torres A, Rossi P, **Ramirez JA**, Community-Acquired Pneumonia Organization (CAPO) Investigators. Improving

- outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. *Arch Intern Med*. 2009 Sep;169(16):1515–24 <https://doi.org/10.1001/archinternmed.2009.265> PMID:19752410
99. Mirsaedi M, Peyrani P, Aliberti S, Filardo G, Bordon J, Blasi F, **Ramirez JA**. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. *Chest*. 2010 Feb;137(2):416–20 <https://doi.org/10.1378/chest.09-0998> PMID:19837825
100. Isturiz RE, Luna CM, **Ramirez J**. Clinical and economic burden of pneumonia among adults in Latin America. *International Journal of Infectious Diseases*. 2010 Oct 1;14(10):e852-6
101. Arnold FW, Brock GN, Peyrani P, Rodríguez EL, Díaz AA, Rossi P, et al. **Ramirez JA**; for the CAPO authors. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. *Respir Med*. 2010 Nov;104(11):1736–43. <https://doi.org/10.1016/j.rmed.2010.05.022> PMID:20576417
102. Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, Gaito S, **Ramirez JA**. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. *Eur Respir J*. 2010 Jul;36(1):128–34 <https://doi.org/10.1183/09031936.00130909> PMID:19926738
103. Barve S, Kapoor R, Moghe A, Ramirez JA, Eaton JW, Gobejishvili L, et al. Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV-infected patients. *Alcohol Res Health*. 2010;33(3):229–36. PMID:23584064
104. Haque NZ, Cahuayme Zuniga L, Peyrani P, Reyes K, Lamerato L, Moore CL, **Ramirez JA**, Zervos MJ, and Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators. Relationship of Vancomycin MIC to Mortality in Patients with Methicillin-Resistant *Staphylococcus aureus* Hospital-Acquired, Ventilator-Associated and Healthcare-Associated Pneumonia. *Chest*. 2010 Dec;138(6):1356–62 <https://doi.org/10.1378/chest.09-2453> PMID:20558550107.
105. Bordon J, Wiemken T, Peyrani P, Paz ML, Gnoni M, Cabral P, del Carmen Venero M, **Ramirez J**, CAPO Study Group. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. *Chest*. 2010 Aug 1;138(2):279-83 <https://doi.org/10.1378/chest.09-2702> PMID:20382718
106. Riquelme R, Riquelme M, Rioseco ML, Inzunza C, Gomez Y, Contreras C, Riquelme J, Peyrani P, Wiemken T, **Ramirez J**. Characteristics of hospitalized patients with 2009 H1N1 influenza in Chile. *Eur Respir J*. 2010 Feb;36(4):864–9 <https://doi.org/10.1183/09031936.00180409>
107. Bordon J, Master RN, Clark RB, Duvvuri P, Karlowky JA, Ayesu K, Klotchko A, Kapoor R, **Ramirez J**. Methicillin-resistant *Staphylococcus aureus* resistance to non- β -lactam antimicrobials in the United States from 1996 to 2008. *Diagnostic microbiology and infectious disease*. 2010 Aug 1;67(4):395-8 <https://doi.org/10.1016/j.diagmicrobio.2010.03.006> PMID:20638612
108. Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, Cely CM, Ford KD, Scerpella EG, **Ramirez JA**; Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. *Lancet Infect Dis*. 2011 Mar;11(3):181–9 [https://doi.org/10.1016/S1473-3099\(10\)70314-5](https://doi.org/10.1016/S1473-3099(10)70314-5) PMID:21256086
109. Mangino JE, Peyrani P, Ford KD, Kett DH, Zervos MJ, Welch VL, Scerpella EG, **Ramirez JA**. Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy of Hospital-

Acquired Pneumonia (IMPACT-HAP) study. Crit Care. 2011;15(1):R38. <https://doi.org/10.1186/cc9988> PMID:21266065

110. Aliberti S, Peyrani P, Filardo G, Mirsaeidi M, Amir A, Blasi F, **Ramirez JA**. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest. 2011 Aug;140(2):482–8. <https://doi.org/10.1378/chest.10-2895> PMID:21330383
111. Riquelme R, Jimenez P, Videla AJ, Lopez H, Chalmers J, Singanayagam A, Riquelme M, Peyrani P, Wiemken T, Arbo G, Benchetrit G, Rioseco ML, Ayesu K, Klotchko A, Marzoratti L, Raya M, Figueroa S, Saavedra F, Pryluka D, Inzunza C, Torres A, Alvare P, Fernandez P, Barros M, Gomez Y, Contreras C, Rello J, Bordon J, Feldman C, Arnold F, Nakamatsu R, Riquelme J, Blasi F, Aliberti S, Cosentini R, Lopardo G, Gnoni M, Welte T, Saad M, Guardiola J, **Ramirez J**. Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia. The International Journal of Tuberculosis and Lung Disease. 2011 Apr 1;15(4):542-6 <https://doi.org/10.5588/ijtld.10.0539> PMID:21396216
112. Moffett BK, Panchabhai TS, Anaya I, Nakamatsu R, Arnold FW, Peyrani P, Wiemken T, Guardiola J, **Ramirez JA**. Computed tomography measurements of parapneumonic effusion indicative of thoracentesis. Eur Respir J. 2011 Dec;38(6):1406–11 <https://doi.org/10.1183/09031936.00004511> PMID:21622586
113. Aliberti S, Ramirez J, Cosentini R, Brambilla AM, Zanaboni AM, Rossetti V, Tarsia P, Peyrani P, Piffer F, Blasi F. Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. Respiratory medicine. 2011 Nov 1;105(11):1732-8 <https://doi.org/10.1016/j.rmed.2011.07.006> PMID:21821405
114. Peyrani P, Wiemken T, Arnold F, Ramirez J. **Ramirez J**. Developing an international network for clinical research: the Community-Acquired Pneumonia Organization experience. Clin Investig (Lond). 2011;1(1):13–8.
115. Peyrani P, Allen M, Wiemken TL, Haque NZ, Zervos MJ, Ford KD, Scerpella EG, Mangino JE, Kett DH, **Ramirez JA**, IMPACT-HAP Study Group. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Pantone-Valentine leukocidin gene. Clin Infect Dis. 2011 Oct;53(8):766–71 <https://doi.org/10.1093/cid/cir541> PMID:21880581
116. Bordon J, Kapoor R, Martinez C, Portela D, Duvvuri P, Klochko A, Ayesu K, Peyrani P, Cillóniz C, Wiemken T, Parra A, Torres A, Rello J, **Ramirez J**. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. Int J Infect Dis. 2011 Dec;15(12):e822–7 <https://doi.org/10.1016/j.ijid.2011.05.021> PMID:21885316
117. Wiemken T, Peyrani P, Arnold FW, **Ramirez J**. The use of large databases to study pneumonia: what is their value? Clin Chest Med. 2011 Sep;32(3):481–9. <https://doi.org/10.1016/j.ccm.2011.05.007> PMID:21867817
118. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii3–9 <https://doi.org/10.1093/jac/dkr094> PMID:21482567
119. Brock GN, Barnes C, **Ramirez JA**, Myers J. How to handle mortality when investigating length of hospital stay and time to clinical stability. BMC Med Res Methodol. 2011 Oct;11(1):144. <https://doi.org/10.1186/1471-2288-11-144> PMID:22029846
120. **Ramirez JA**. The challenge of predicting influenza. Front Microbiol. 2011 Mar 9;2:45. <https://doi.org/10.3389/fmicb.2011.00045> PMID:21833304

121. Master RN, Clark RB, Karlowsky JA, **Ramirez J**, Bordon JM. Analysis of resistance, cross-resistance and antimicrobial combinations for *Pseudomonas aeruginosa* isolates from 1997 to 2009. *Int J Antimicrob Agents*. 2011 Oct;38(4):291–5
<https://doi.org/10.1016/j.ijantimicag.2011.04.022> PMID:21737249
122. Kasuya Y, Hargett JL, Lenhardt R, Heine MF, Doufas AG, Rimmel KS, **Ramirez JA**, Akça O. Ventilator-associated pneumonia in critically ill stroke patients: frequency, risk factors, and outcomes. *J Crit Care*. 2011 Jun;26(3):273–9 <https://doi.org/10.1016/j.jcrc.2010.09.006>
PMID:21106334
123. Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG, Ford KD, Zervos MJ, **Ramirez JA**, Kett DH, Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. *Clin Ther*. 2012 Jan;34(1):149–57
<https://doi.org/10.1016/j.clinthera.2011.12.013> PMID:22284995
124. Peyrani P, Allen M, Seligson D, Roberts C, Chen A, Haque N, Zervos M, Wiemken T, Harting J, Christensen D, **Ramirez J**. Clinical outcomes of patients with osteomyelitis infected with MRSA USA-300 strains [Belle Mead NJ]. *Am J Orthop*. 2012 Mar;41(3):117–22. PMID:22530208
125. Wiemken TL, Peyrani P, **Ramirez JA**. Global changes in the epidemiology of community-acquired pneumonia. *Semin Respir Crit Care Med*. 2012 Jun;33(3):213–9. <https://doi.org/10.1055/s-0032-1315633> PMID:22718207
126. Wiemken TL, **Ramirez JA**, Polgreen P, Peyrani P, Carrico RM. Evaluation of the knowledge-sharing social network of hospital-based infection preventionists in Kentucky. *American journal of infection control*. 2012 Jun 1;40(5):440-5.
127. Haddy RI, Richmond BW, Trapese FM, Fannin KZ, **Ramirez JA**. Septicemia in patients with AIDS admitted to a university health system: a case series of eighty-three patients. *J Am Board Fam Med*. 2012 May-Jun;25(3):318–22 <https://doi.org/10.3122/jabfm.2012.03.110106> PMID:22570395
128. Borel N, Pospischil A, Dowling RD, Dumrese C, Gaydos CA, Bunk S, Hermann C, **Ramirez JA**, Summersgill JT. Antigens of persistent *Chlamydia pneumoniae* within coronary atheroma from patients undergoing heart transplantation. *J Clin Pathol*. 2012 Feb;65(171e177):171–7
<https://doi.org/10.1136/jclinpath-2011-200270> PMID:22049224
129. Haque NZ, Arshad S, Peyrani P, Ford KD, Perri MB, Jacobsen G, Reyes K, Scerpella EG, **Ramirez JA**, Zervos MJ. Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol*. 2012 May;50(5):1640–4 <https://doi.org/10.1128/JCM.06701-11> PMID:22337980
130. **Ramirez JA**, Cooper AC, Wiemken T, Gardiner D, Babinchak T; 308 Study Group. Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin. *BMC Infect Dis*. 2012 Jul;12(1):159. <https://doi.org/10.1186/1471-2334-12-159> PMID:22812672
131. Wiemken T, Polgreen PM, McKinney WP, **Ramirez J**, Just E, Carrico R. Knowledge sharing among healthcare infection preventionists: the impact of public health professionals in a rural state. *BMC Res Notes*. 2012 Jul;5(1):387. <https://doi.org/10.1186/1756-0500-5-387> PMID:22838734
132. Aliberti S, Zanaboni AM, Wiemken T, Nahas A, Uppatla S, Morlacchi LC, Peyrani P, Blasi F, **Ramirez J**. Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. *European Respiratory Journal*. 2013 Sep 1;42(3):742-9.
<https://doi.org/10.1183/09031936.00100812> PMID:23143544

133. **Ramirez JA**. Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet? *Eur Respir J*. 2013 Jan;41(1):5–6. <https://doi.org/10.1183/09031936.00093112> PMID:23277515
134. Griffin AT, Peyrani P, Wiemken TL, Ramirez JA, Arnold FW. Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia. *Infection*. 2013 Apr 1;41(2):517-23. <https://doi.org/10.1007/s15010-012-0363-1> PMID:23132663
135. Arnold FW, Wiemken TL, Peyrani P, **Ramirez JA**, Brock GN; CAPO authors. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. *Respir Med*. 2013 Jul;107(7):1101–11. <https://doi.org/10.1016/j.rmed.2013.04.003> PMID:23660396
136. Arnold FW, Wiemken T, Peyrani P, Mirsaeidi M. **Ramirez JA**, CAPO study group. Outcomes in females hospitalized with community-acquired pneumonia are worse than males. *Eur Respir J*. 2013; 41:1135-40. <https://doi.org/10.1183/09031936.00046212>
137. Wiemken T, Kelley R, **Ramirez J**. Clinical scoring tools: which is best to predict clinical response and long-term outcomes? *Infect Dis Clin North Am*. 2013 Mar;27(1):33–48. <https://doi.org/10.1016/j.idc.2012.11.015> PMID:23398864
138. Bordon J, Aliberti S, Duvvuri P, Wiemken T, Peyrani P, Natividad I, Caceres-Lara A, Delapenha R, Blasi F, **Ramirez J**. Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes. *Int J Infect Dis*. 2013 May;17(5):e293–8 <https://doi.org/10.1016/j.ijid.2012.09.021> PMID:23507237
139. Bordon J, Aliberti S, Duvvuri P, Wiemken T, Peyrani P, Natividad I, Caceres-Lara A, Delapenha R, Blasi F, **Ramirez J**. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. *Int J Infect Dis*. 2013 Feb;17(2):e76–83 <https://doi.org/10.1016/j.ijid.2012.06.006> PMID:23069683
140. Bordon JM, Uriarte S, Arnold FW, Fernandez-Botran R, Rane M, Peyrani P, Cavallazzi R, Saad M, **Ramirez J**. Cytokines and neutrophils responses in influenza pneumonia. *Infection*. 2013 Oct;41(5):1021–4. <https://doi.org/10.1007/s15010-013-0461-8> PMID:23589279
141. Caceres F, Welch VL, Kett DH, Scerpella EG, Peyrani P, Ford KD, **Ramirez JA**; Impact-Hap Study Group. Absence of gender-based differences in outcome of patients with hospital-acquired pneumonia. *J Womens Health (Larchmt)*. 2013 Dec;22(12):1069–75 <https://doi.org/10.1089/jwh.2013.4434> PMID:24128006
142. Camp JV, Chu YK, Chung DH, McAllister RC, Adcock RS, Gerlach RL, Wiemken TL, Peyrani P, **Ramirez JA**, Summersgill JT, Jonsson CB. Phenotypic Differences in Virulence and Immune Response in Closely Related Clinical Isolates of Influenza a 2009 H1n1 Pandemic Viruses in Mice. *PLoS One*. 2013 Feb 18;8(2):e56602. <https://doi.org/10.1371/journal.pone.0056602> PMID:23441208
143. Griffin AT, Peyrani P, Wiemken TL, **Ramirez JA**, Arnold FW. Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia. *Infection*. 2013 Apr;41(2):517–23. <https://doi.org/10.1007/s15010-012-0363-1> PMID:23132663
144. Liapikou A, Polverino E, Cilloniz C, Peyrani P. **Ramirez J**, Menendez R, Torres A. A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared to Community-Acquired Pneumonia. *Respir Care*. 2014 Jul;59(7):1078-85 Epub 2013 Nov 5 <https://doi.org/10.4187/respcare.02788> PMID: 24194575

145. Pasquale TR, Jabrocki B, Salstrom SJ, Wiemken TL, Peyrani P, Haque NZ, Scerpella EG, Ford KD, Zervos MJ, **Ramirez JA**, File Jr TM. Emergence of methicillin-resistant *Staphylococcus aureus* USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA. *Int J Infect Dis*. 2013 Jun;17(6):e398–403. <https://doi.org/10.1016/j.ijid.2012.12.013> PMID:23375542
146. Peyrani P, **Ramirez J**. What is the association of cardiovascular events with clinical failure in patients with community-acquired pneumonia? *Infect Dis Clin North Am*. 2013 Mar;27(1):205–10. <https://doi.org/10.1016/j.idc.2012.11.010> PMID:23398875
147. **Ramirez J**, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. *Antimicrob Agents Chemother*. 2013 Apr;57(4):1756–62. <https://doi.org/10.1128/AAC.01232-12> PMID:23357775
148. Wiemken T, Peyrani P, Bryant K, Kelley RR, Summersgill J, Arnold F, Carrico R, McKinney Wp, Jonsson C, Carrico K, **Ramirez J**. Incidence of respiratory viruses in patients with community-acquired pneumonia admitted to the intensive care unit: results from the Severe Influenza Pneumonia Surveillance (SIPS) project. *Eur J Clin Microbiol Infect Dis*. 2013 May;32(5):705–10. <https://doi.org/10.1007/s10096-012-1802-8> PMID:23274861
149. Batson N, Batson L, Peters CK, Wiemken T, Kelley R, **Ramirez JA**. Collaboration with clinical and translational sciences to improve psychiatry training in research. *Academic Psychiatry*. (Nov 2013) 1;37(6):426–428. PMID: 24185292.
150. Aliberti S, Brambilla AM, Chalmers JD, Cilloniz C, **Ramirez J**, Bignamini A, et al. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. *Respir Res*. 2014 Mar;15(1):27. <https://doi.org/10.1186/1465-9921-15-27> PMID:24593040
151. Arshad S, Shoyinka A, Perri MB, Moreno D, Jacobsen G, Zervos MJ; IMPACT-HAP Study Group. USA600 Methicillin-Resistant *Staphylococcus aureus* in ICU Patients With Pneumonia. A Case-Control Study Design to Evaluate Epidemiology and Outcomes of an Emerging Strain. *Infect Dis Clin Pract*. 2014;22(2):85–8 <https://doi.org/10.1097/ipc.0b013e318298b81c>
152. Cavallazzi R, Wiemken T, Christensen D, Peyrani P, Blasi F, Levy G, Aliberti S, Kelley R, **Ramirez J**, Community-Acquired Pneumonia Organization (CAPO) Investigators. Predicting *Mycobacterium tuberculosis* in patients with community-acquired pneumonia. *Eur Respir J*. 2014 Jan;43(1):178–84 <https://doi.org/10.1183/09031936.00017813> PMID:23794467
153. Wiemken TL, Kelley RR, Pacholski EB, Carrico KW, Peyrani P, Carrico RM, **Ramirez JA**. The role of infection prevention conferences to build and maintain knowledge-sharing networks: a longitudinal evaluation. *Am J Infect Control*. 2014 Feb;42(2):209–11 <https://doi.org/10.1016/j.ajic.2013.07.018> PMID:24355491
154. Wiemken TL, Curran DR, Pacholski EB, Kelley RR, Abdelfattah RR, Carrico RM, **Ramirez JA**. The value of ready-to-use disinfectant wipes: compliance, employee time, and costs. *Am J Infect Control*. 2014 Mar;42(3):329–30 <https://doi.org/10.1016/j.ajic.2013.09.031> PMID:24581022
155. Aliberti S, **Ramirez JA**. Cardiac Diseases Complicating Community-Acquired Pneumonia. *Current opinion in infectious diseases*. 2014 Jun 1;27(3):295–301 <https://doi.org/10.1097/QCO.0000000000000055>.
156. Cavallazzi R, Wiemken T, **Ramirez J**. Risk factors for pulmonary tuberculosis in community-acquired pneumonia. *Eur Respir J*. 2014 Apr;43(4):1214 <https://doi.org/10.1183/09031936.00167113> PMID:24687677

157. Wiemken TL, Carrico RM, Klein SL, Jonsson CB, Peyrani P, Kelley RR, Alibeti S, Blasi F, Fernandez-Gonzalez R, Lopardo G, **Ramirez JA**; CAPO Investigators. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to *Streptococcus pneumoniae* community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. *Vaccine*. 2014 Apr;32(19):2198–203 <https://doi.org/10.1016/j.vaccine.2014.02.048> PMID:24613522
158. Levy G, Perez M, Rodríguez B, Voth AH, Perez J, Gnoni M, Kelley R, Wiemken T, **Ramirez J**. Adherence with national guidelines in hospitalized patients with community-acquired pneumonia: results from the CAPO study in Venezuela [English Edition]. *Arch Bronconeumol*. 2015 Apr;51(4):163–8 <https://doi.org/10.1016/j.arbr.2015.02.005> PMID:24809678
159. Wiemken TL, Curran D, Kelley RR, Khan MS, Carrico RM, Pacholski EB, **Ramirez JA**. A single genotype of *Acinetobacter baumannii* expresses multiple antibiotic susceptibility phenotypes. *Am J Infect Control*. 2014 May;42(5):556–8 <https://doi.org/10.1016/j.ajic.2014.01.003> PMID:24773796
160. Peyrani P, Wiemken TL, Kelley R, Zervos MJ, Kett DH, File Jr TM, Stein GE, Ford KD, Scerpella EG, Welch V, **Ramirez JA**. IMPACT-HAP Study Group. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant *Staphylococcus aureus* treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. *Crit Care*. 2014 Jun;18(3):R118. <https://doi.org/10.1186/cc13914> PMID:24916853
161. Fernandez-Botran R, Uriarte SM, Arnold FW, Rodriguez-Hernandez L, Rane MJ, Peyrani P, Wiemken T, Kelley R, Uppatla S, Cavallazzi R, Blasi F, Morlachhi L, Aliberti S, Jonsoon C, **Ramirez JA**, Bordon J. Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia. *Inflammation*. 2014 Aug 1;37(4):1158–66 <https://doi.org/10.1007/s10753-014-9840-2>
162. Wiemken TL, Curran DR, Kelley RR, Pacholski EB, Carrico RM, Peyrani P, Khan MS, **Ramirez JA**. Evaluation of the effectiveness of improved hydrogen peroxide in the operating room. *Am J Infect Control*. 2014 Sep;42(9):1004–5 <https://doi.org/10.1016/j.ajic.2014.05.002> PMID:24939514
163. Haubitz S, Hitz F, Graedel L, Batschwaroff M, Wiemken TL, Peyrani P, **Ramirez JA**, Fux CA, Mueller B, Schuetz P. “Ruling out *Legionella* in community-acquired pneumonia.” *American Journal of Medicine* 127, no. 10 (Oct 2014):1010.e11–9.
164. Cavallazzi R, El-Kersh K, Abu-Atherah E, Singh S, Loke YK, Wiemken T, **Ramirez J**. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review. *Respir Med*. 2014 Nov;108(11):1569–80 <https://doi.org/10.1016/j.rmed.2014.09.018> PMID:25448309
165. Kelley RR, Mattingly WA, Wiemken TL, Khan M, Coats D, Curran D, Chariker JH, **Ramirez J**. Visual grids for managing data completeness in clinical research datasets. *J Biomed Inform*. 2015 Apr;54:337–44 <https://doi.org/10.1016/j.jbi.2014.12.002> PMID:25554683
166. Bordon JM, Fernandez-Botran R, Wiemken TL, Peyrani P, Uriarte SM, Arnold FW, Rodriguez-Hernandez L, Rane MJ, Kelley RR, Binford LE, Uppatla S, Cavalazzi R, Blasi F, Aliberti S, Restrepo MI, Fazeli S, Mathur A, Rahmani M, Ayesu K, **Ramirez J**. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response. *Infection*. 2015 Dec;43(6):729–38 <https://doi.org/10.1007/s15010-015-0837-z> PMID:26424683
167. Carrico R, Bosson R, Koch J, Raghuram A, Peyrani P, Ford R, Pauly A, Rivera KC, Abdulmogith T, Johnson W, Van Heiden SC, Balcom D, Smith M, Wiemken T, **Ramirez J**. Addressing the challenges of refugee health: Experiences from the University of Louisville interprofessional refugee immunization clinic. *J Nurs Educ Pract*. 2015 Sep;5(12):88 <https://doi.org/10.5430/jnep.v5n12p88>

168. Wiemken TL, Kelley RR, Carrico RM, Binford LE, Guinn BE, Mattingly WA, Peyrani P, **Ramirez JA**. Efficacy of a novel skin antiseptic against carbapenem-resistant Enterobacteriaceae. *Am J Infect Control*. 2015 Apr;43(4):380–2 <https://doi.org/10.1016/j.ajic.2014.12.007> PMID:25660077
169. Lanspa MJ, Peyrani P, Wiemken T, Wilson EL, **Ramirez JA**, Dean NC. Characteristics associated with clinician diagnosis of aspiration pneumonia: a descriptive study of afflicted patients and their outcomes. *J Hosp Med*. 2015 Feb;10(2):90–6 <https://doi.org/10.1002/jhm.2280> PMID:25363892
170. Aliberti S, Giuliani F, **Ramirez J**, Blasi F; DURATION Study Group. How to choose the duration of antibiotic therapy in patients with pneumonia. *Curr Opin Infect Dis*. 2015 Apr;28(2):177–84. <https://doi.org/10.1097/QCO.000000000000140> PMID:25692271
171. Peyrani P, **Ramirez J**. What is the best therapeutic approach to methicillin-resistant *Staphylococcus aureus* pneumonia? *Curr Opin Infect Dis*. 2015 Apr;28(2):164–70 <https://doi.org/10.1097/QCO.000000000000149> PMID:25692268
172. Cavallazzi R, Wiemken T, Arnold FW, Luna CM, Bordon J, Kelley R, Feldman C, Chalmers JD, Torres A, **Ramirez J**. Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. *Respiratory medicine*. 2015 Jun 1;109(6):743–50. <https://doi.org/10.1016/j.rmed.2015.04.007> PMID:25956021
173. Wiemken TL, Venkatakrisha RJ, Kelley RR, Peyrani P, Mattingly WA, Arnold FW, Cabral PW, Cavallazzi R, Haribabu B, **Ramirez JA**. The upper respiratory tract microbiome of hospitalised patients with community-acquired pneumonia of unknown aetiology: A pilot study. *Pneumonia*. 2015 Dec;6(1):83–9 <https://doi.org/10.15172/pneu.2015.6/682>
174. Carugati M, Franzetti F, Wiemken T, Kelly R, Peyrani P, Blasi F, **Ramirez J**, Aliberti S. De-escalation therapy among bacteraemic patients with community-acquired pneumonia. *Clin Microbiol Infect*. 2016 Oct;21(10):936.e11–8 <https://doi.org/10.1016/j.cmi.2015.06.015> PMID:26115864
175. Burk M, El-Kersh K, Saad M, Wiemken T, **Ramirez J**, Cavallazzi R. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. *Eur Respir Rev*. 2016 Jun;25(140):178–88. <https://doi.org/10.1183/16000617.0076-2015> PMID:27246595
176. Wiemken TL, Powell W, Carrico RM, Mattingly WA, Kelley RR, Furmanek SP, Johnson D, **Ramirez JA**. Disinfectant sprays versus wipes: Applications in behavioral health. *Am J Infect Control*. 2016 Dec;44(12):1698–9 <https://doi.org/10.1016/j.ajic.2016.05.028> PMID:27590110
177. Luna CM, Palma I, Niederman MS, Membriani E, Giovini V, Wiemken TL, Peyrani P, **Ramirez J**. The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-Acquired Pneumonia. *Ann Am Thorac Soc*. 2016 Sep;13(9):1519–26. <https://doi.org/10.1513/AnnalsATS.201512-848OC> PMID:27398827
178. Moffett BK, Panchabhai TS, Nakamatsu R, Arnold FW, Peyrani P, Wiemken T, Guardiola J, **Ramirez JA**. Comparing posteroanterior with lateral and anteroposterior chest radiography in the initial detection of parapneumonic effusions. *The American journal of emergency medicine*. 2016 Dec 1;34(12):2402–7 <https://doi.org/10.1016/j.ajem.2016.09.021> PMID:27793503
179. Arnold FW, Summersgill JT, **Ramirez JA**. Role of Atypical Pathogens in the Etiology of Community-acquired Pneumonia. *Semin Respir Crit Care Med*. 2016 Dec;37(6) 819–828. doi:10.1055/s-0036-1592121. PMID: 27960206.
180. Egger ME, Myers JA, Arnold FW, Pass LA, **Ramirez JA**, Brock GN. Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Acquired Pneumonia. *BMC Med Inform Decis Mak*. 2016 Dec;16(1):34. <https://doi.org/10.1186/s12911-016-0270-y> PMID:26976388

181. Wiemken TL, Kelley RR, Fernandez-Botran R, Mattingly WA, Arnold FW, Furmanek SP, Restrepo MI, Chalmers JD, Peyrani P, Cavallazzi R, Bordon J, Aliberti S, **Ramirez JA**. Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study. *Univ Louisville J Respir Infect*. 2017;1(1):3–11 <https://doi.org/10.18297/jri/vol1/iss1/1/> PMID:28393141
182. Perez San Juan J, Rodriguez Hernandez L, Wiemken TL, Kelley RR, Fernandez-Botran R, Gnoni M, Peyrani P, Rane MJ, Arnold FW, **Ramirez JA**, Uriarte S. Neutrophil Function in Elderly Patients Hospitalized with Community-Acquired Pneumonia. *Univ Louisville J Respir Infect*. 2017;1(1):3 DOI: 10.18297/jri/vol1/iss1/3 <https://ir.library.louisville.edu/jri/vol1/iss1/3>
183. Peyrani P, Wiemken TL, Zervos MJ, Kett DH, File Jr TM, Stein GE, Ford KD, **Ramirez JA**. Time to Clinical Stability in Patients with Ventilator-Associated Pneumonia due to Methicillin-Resistant *Staphylococcus aureus* Treated with Linezolid versus Vancomycin: Results from the IMPACT-HAP Study. *Univ Louisville J Respir Infect*. 2017;1(1):4. <https://doi.org/10.18297/jri/vol1/iss1/4>.
184. Carrico RM, Wiemken TL, Bosson R, Mattingly WA, Ford R, Van Heiden S, Kotey S, **Ramirez JA**. Health Profiles of Newly Arriving Refugees in Kentucky, 2016: Data from the University of Louisville Global Health Program. *Journal of Refugee & Global Health*. 2017;1(1):2 DOI:10.18297/rgh/vol1/iss1/2/ <https://ir.library.louisville.edu/rgh/vol1/iss1/2>
185. Bosson R, Schlaudt VA, Williams MT, Carrico RM, Peña A, **Ramirez JA**, Kanter J. Evaluating Mental Health in Cuban Refugees: The Role of the Refugee Health Screener-15. *Journal of Refugee & Global Health*. 2017;1(1):4. <https://doi.org/10.18297/rgh/vol1/iss1/4>
186. Carrico RM, Mitchell C, Balcom D, Goss L, Persaud A, Mutsch K, Wiemken TL, Bosson R, **Ramirez JA**. Use of Emergency Department for Care Access by Refugees Resettling in Kentucky, 2015: Findings from the University of Louisville Global Health Center. *Journal of Refugee & Global Health*. 2017;1(1):5 <https://doi.org/10.18297/rgh/vol1/iss1/5/>
187. Fernandez-Botran R, Wiemken TL, Kelley RR, Peyrani P, Bordon J, Cavallazzi R, **Ramirez JA**. Analysis of the Local and Systemic Cytokine Response Profiles in Patients with Community-Acquired Pneumonia. Relationship with Disease Severity and Outcomes. *Univ Louisville J Respir Infect*. 2017;1(3):5 <https://doi.org/10.18297/jri/vol1/iss3/5/>
188. Maurici R, Morello Gearhart A, Viríssimo Maciel V, Arnold F, Fernandez F, Persaud AK, Furmanek S, Wiemken T, **Ramirez J**, Cavallazzi R. The Presence of COPD does not Influence Clinical Outcomes in Hospitalized Patients with Community-acquired Pneumonia. *Univ Louisville J Respir Infect*. 2017;1(3):8 <https://doi.org/10.18297/jri/vol1/iss3/8/>
189. Mattingly WA, Wiemken TL, Furmanek SP, Peyrani P, Kelley RR, **Ramirez JA**. The Community-Acquired Pneumonia Organization (CAPO) Cloud-Based Research Platform (the CAPO-Cloud): Facilitating Data Sharing in Clinical Research. *Univ Louisville J Respir Infect*. 2017;1(3):9. <https://doi.org/10.18297/jri/vol1/iss3/9/>.
190. Wiemken TL, Furmanek SP, Mattingly WA, Guinn BE, Cavallazzi R, Fernandez-Botran R, Wolf LA, English CL, **Ramirez JA**. Predicting 30-day mortality in hospitalized patients with community-acquired pneumonia using statistical and machine learning approaches. *Univ Louisville J Respir Infect*. 2017;1(3):10. <https://doi.org/10.18297/jri/vol1/iss3/10/>.
191. Cavallazzi R, **Ramirez JA**. Using Steroids in Patients with Community-Acquired Pneumonia at the University of Louisville Hospital: Who, What, and When. *Univ Louisville J Respir Infect*. 2017;1(4):1. <https://doi.org/10.18297/jri/vol1/iss4/1>.
192. Van Heiden S, Carrico R, Wiemken TL, Alexander R, McLaughlin JM, Jiang Q, Peyrani P, Mattingly WA, Furmanek SP, English CL, Pena S, Isturiz R, **Ramirez JA**. Level of Recall Bias Regarding Pneumococcal Vaccination History among Adults Hospitalized with Community-

Acquired Pneumonia: Results from the University of Louisville Pneumonia Study. *Univ Louisville J Respir Infect.* 2017;1(4):3 <https://doi.org/10.18297/jri/vol1/iss4/3>.

193. Morello Gearhart A, Cavallazzi R, Peyrani P, Wiemken TL, Furmanek SP, Reyes-Vega A, Gauhar U, Rivas-Perez H, Roman J, **Ramirez JA**, Fernandez-Botran R. Lung Cytokines and Systemic Inflammation in Patients with COPD. *Univ Louisville J Respir Infect.* 2017;1(4):4 <https://doi.org/10.18297/jri/vol1/iss4/4>.
194. Beavin LA, Arnold FW, Peyrani P, Raghuram A, Newman D, Smith R, Sciortino C, Furmanek SP, Carrico RM, **Ramirez JA**. Antimicrobial Stewardship in Hospitalized Patients with Respiratory Infections: Ten-Year Experience from the Robley Rex Louisville VA Medical Center. *Univ Louisville J Respir Infect.* 2017;1(4):7 <https://doi.org/10.18297/jri/vol1/iss4/7>.
195. Alexander R, Peyrani P, Ramirez JA, Self WH, Grijalva C, Counselman F, et al. **Ramirez JA**, Self MD, Wesley H, Grijalva C, Counselman F, Volturo GA, Kabler H, Ostrosky-Zeichner L, Wunderink R. Rationale and Methods of the Study Protocol: Streptococcus pneumoniae Serotypes in Adults 18 Years and Older with Radiographically-Confirmed Community-Acquired Pneumonia (CAP). *Univ Louisville J Respir Infect.* 2017;1(4):8. <https://doi.org/10.18297/jri/vol1/iss4/8>.
196. Peyrani P, **Ramirez JA**. One-Year Mortality in Patients with Community-Acquired Pneumonia. *Univ Louisville J Respir Infect.* 2017;1(4):10 <https://doi.org/10.18297/jri/vol1/iss4/10>
197. Peyrani P, **Ramirez J**. Long-term Mortality in Hospitalized Patients With Community-Acquired Pneumonia. *Am J Med Sci.* 2017 May;353(5):421 <https://doi.org/10.1016/j.amjms.2017.04.008> PMID:28502325
198. Wiemken TL, Furmanek SP, Carrico RM, Mattingly WA, Persaud AK, Guinn BE, et al. Process control charts in infection prevention: make it simple to make it happen. *Am J Infect Control.* 2017 Mar;45(3):216–21 <https://doi.org/10.1016/j.ajic.2016.09.021> PMID:27876163
199. Carrico RM, Goss L, Wiemken TL, Bosson RS, Peyrani P, Mattingly WA, Pauly A, Ford RA, Kotey S, **Ramirez JA**. Infection prevention and control and the refugee population: Experiences from the University of Louisville Global Health Center. *Am J Infect Control.* 2017 Jun;45(6):673-6. <https://doi.org/10.1016/j.ajic.2017.02.032> PMID:28431845
200. **Ramirez JA**, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, Nakamatsu R, Pena S, Guinn BE, Furmanek SP, Persaud AK and University of Louisville Pneumonia Study Group. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. *Clin Infect Dis.* 2017 Nov;65(11):1806-12 <https://doi.org/10.1093/cid/cix647> PMID:29020164
201. Aliberti S, **Ramirez J**, Giuliani F, Wiemken T, Sotgiu G, Tedeschi S, Carugati M, Valenti V, Marchioni M, Camera M, Piro R. Individualizing duration of antibiotic therapy in community-acquired pneumonia. *Pulmonary pharmacology & therapeutics. Pulm Pharmacol Ther.* 2017 Aug;45:191–201 <https://doi.org/10.1016/j.pupt.2017.06.008> PMID:28666965
202. Harting J, Fernandez F, Kelley R, Wiemken T, Peyrani P, **Ramirez J**. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections. *Diagn Microbiol Infect Dis.* 2017 Dec;89(4):294–9 <https://doi.org/10.1016/j.diagmicrobio.2017.09.004> PMID:29137718
203. **Ramirez JA**, File T, Musher D. Duration of antibiotic therapy for patients with bacteremic Staphylococcus aureus community-acquired pneumonia. *Univ Louisville J Respir Infect.* 2018;2(1):1. <https://doi.org/10.18297/jri/vol2/iss1/1/>.
204. **Ramirez J**, Garrity-Ryan L, Chitra S, Kirsch C, Manley A, Tzanis E, Mcgovern PC. Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP). *European Respiratory Journal.* 2018 52:PA5465. DOI: 10.1183/13993003.congress-2018.PA5465

205. Beavin LA, Furmanek SP, Peyrani P, Raghuram A, Arnold FW, Burns M, **Ramirez JA**. Adult Patients Living with Human Immunodeficiency Virus Hospitalized for Community-Acquired Pneumonia in the United States: Incidence and Outcomes. *Univ Louisville J Respir Infect*. 2018;2(1):4. <https://doi.org/10.18297/jri/vol2/iss1/4/>
206. Salunkhe V, Peyrani P, Beavin LA, Furmanek SP, **Ramirez JA**. Characteristics and Clinical Outcomes of Hospitalized Patients with Community-Acquired Pneumonia who are Active Intravenous Drug Users. *Univ Louisville J Respir Infect*. 2018;2(2):3. <https://doi.org/10.18297/jri/vol2/iss2/3/>.
207. Peyrani P, Wiemken TL, Metersky ML, Arnold FW, Mattingly WA, Feldman C, Cavallazzi R, Fernandez-Botran R, Bordon J, **Ramirez JA**. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization. *Infect Dis (Lond)*. 2018 Jan;50(1):13–20 <https://doi.org/10.1080/23744235.2017.1350881> PMID:28699429
208. Wiemken TL, Furmanek SP, Mattingly WA, Wright MO, Persaud AK, Guinn BE, Carrico RM, Arnold FW, **Ramirez JA**. Methods for computational disease surveillance in infection prevention and control: statistical process control versus Twitter’s anomaly and breakout detection algorithms. *Am J Infect Control*. 2018 Feb 1;46(2):124–32 <https://doi.org/10.1016/j.ajic.2017.08.005> PMID:28916373
209. **Ramirez JA**. How can we improve clinical research in pneumonia? *Curr Opin Pulm Med*. 2018 May;24(3):220–6 <https://doi.org/10.1097/MCP.0000000000000469> PMID:29470254
210. Wiemken TL, Furmanek SP, Mattingly WA, Haas J, **Ramirez JA**, Carrico RM. Googling your hand hygiene data: using Google Forms, Google Sheets, and R to collect and automate analysis of hand hygiene compliance monitoring. *Am J Infect Control*. 2018 Jun;46(6):617–9. <https://doi.org/10.1016/j.ajic.2018.01.010> PMID:29496338
211. Dela Cruz CS, Wunderink RG, Christiani DC, Cormier SA, Crothers K, Doerschuk CM, Evans SE, Goldstein DR, Khatri P, Kobzik L, Kolls JK, Levy BD, Metersky ML, Niederman MS, Nusrat R, Orihuela CJ, Peyrani P, Prince AS, **Ramirez JA**, Ridge KM, Sethi S, Suratt BT, Sznajder JI, Tsalik EL, Walkey AJ, Yende S, Aggarwal NR, Caler EV, and Mizgerd JP. Future Research Directions in Pneumonia: NHLBI Working Group Report. *Am J Respir Crit Care Med*. 2018 Jul;198(2):256–63 <https://doi.org/10.1164/rccm.201801-0139WS> PMID:29546996
212. Arnold FW, Lopardo G, Wiemken TL, Kelley R, Peyrani P, Mattingly WA, Feldman C, Gnoni M, Maurici R, **Ramirez JA**, Arnold F, Community-Acquired Pneumonia Organization (CAPO). Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. *Respiratory medicine*. *Respir Med*. 2018 Jul;140:115–21 <https://doi.org/10.1016/j.rmed.2018.05.020> PMID:29957272
213. **Ramirez J**, Peyrani P, Wiemken T, Chaves SS, Fry AM. A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections. *Clin Infect Dis*. 2018 Aug;67(5):736–42. <https://doi.org/10.1093/cid/ciy163> PMID:29659754
214. McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, **Ramirez JA**. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. *Clin Infect Dis*. 2018 Oct;67(10):1498–506. <https://doi.org/10.1093/cid/ciy312> PMID:29790925
215. Chandler T, Furmanek SP, English CL, Glick C, Trail W, Daniels L, Owolabi U, Carrico R, **Ramirez JA**, Wiemken TL. Effectiveness of the Influenza Vaccine in Preventing Hospitalizations of

Patients with Influenza Community-Acquired Pneumonia. *Univ Louisville J Respir Infect*. 2018;2(1):6. <https://doi.org/10.18297/jri/vol2/iss1/6/>.

216. Bassi GL, Comaru T, Martí D, Xiol EA, Chiurazzi C, Traverso C, Carbonara M, Ranzani OT, Amaro R, Frigola G, Fuster C, Saco MA, Zanella A, De Rosa F, Rigol M, Fernandez L, Luque N, **Ramirez J**, Blasi F, Suen J, Fraser J, Torres A. Recruitment manoeuvres dislodge mucus towards the distal airways in an experimental model of severe pneumonia. *Br J Anaesth*. 2018 Nov. <https://doi.org/10.1016/j.bja.2018.07.039>.
217. Roman J, Viegi G, Schenker M, Ojeda VD, Pérez-Stable EJ, Nemery B, Annesi-Maesano I, Patel SR, La Grutta S, Holguin F, Moughrabieh A, Bime C, Lindberg A, Migliori GB, de Vries G, **Ramirez J**, Aliberti S, Feldman C, Celedon JC. Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report. *Ann Am Thorac Soc*. 2018 Nov;15(11):1247–55 <https://doi.org/10.1513/AnnalsATS.201807-478ST> PMID:30382778
218. Cavallazzi R, **Ramirez JA**. Influenza and Viral Pneumonia. *Clin Chest Med*. 2018 Dec;39(4):703–21. <https://doi.org/10.1016/j.ccm.2018.07.005> PMID:30390743
219. Raghuram A, Gnoni M, Wiemken T, Beavin L, Arnold A, Zervos M, Kett D, File T, Stein G, Ford K, **Ramirez JA**, Peyrani P, IMPACT HAP Study Group. Sepsis in patients with ventilator associated pneumonia due to methicillin-resistant *Staphylococcus aureus*: Incidence and impact on clinical outcomes. *Univ Louisville J Respir Infect*. 2017 Apr; 1(3): 3-7. <https://doi.org/10.18297/jri/vol1/iss3/3>
220. **Ramirez JA**, Tzanis E, Curran M, Noble R, Chitra S, Manley A, Kirsch C, McGovern PC. Early clinical response in community-acquired bacterial pneumonia: From clinical endpoint to clinical practice. *Clin Infect Dis*. 2019 Aug;69(IS1):S33-S39. <https://doi.org/10.1093/cid/ciz397>
221. Gearhart AM, Furmanek S, English C, **Ramirez J**, Cavalazzi R. Predicting the need for ICU admission in community-acquired pneumonia. *J Res Med*. 2019 Aug; 155: 61-65. <https://doi.org/10.1016/j.rmed.2019.07.007>

PUBLICATIONS: (Non-Peer Review)

1. **Ramirez J.** Advances in Antibiotic Therapy: Parenteral to Oral Switch. *Clinician (goa)*. 1993;11:38-40.
2. **Ramirez J.** Historia Natural de la Enfermedad por el Virus de la Inmunodeficiencia Humana. *Consultas Medicas*. 1993;6:4-9.
3. **Ramirez J.** Patogenia y Tratamiento de la Infeccion por el Virus de la Inmunodeficiencia Humana. *Consultas Medicas*. 1993;7:18-25.
4. **Ramirez J, Summersgill J.** Rapid Tests for the Diagnosis of Legionella Pulmonary Infections. *Journal of the Kentucky Medical Association*. 1994;92:62-5.
5. Srinath L, Ahkee S, Huang A, Raff M, **Ramirez J.** Acute Miliary Blastomycosis in an HIV Infected Patient. *Journal of the Kentucky Medical Association*. 1994 Nov;92(11):450-2.
6. Ahkee S, Srinath L, Huang A, Raff M, **Ramirez J.** Clinical Significance of Mycobacterium Other Than Tuberculosis Isolated from Respiratory Specimens at a University Hospital. *Journal of the Kentucky Medical Association*. 1995;93(2):53-5.
7. Cheadle W, **Ramirez J.** Treatment of Infectious Diseases, in *Master Series in Surgery: Advances in Trauma and Critical Care*. Master Series in Surgery. 1994 Mar;5:22-40.
8. **Ramirez J, Summersgill J.** The Importance of Accurate Susceptibility Testing. Setting the Standards-Expert Perspectives on Improved Methodology in Antimicrobial Susceptibility Testing and the Optimum Utilization of the Data. England: Wells Medical Limited; 1994.
9. **Ramirez J.** Enfoque del paciente con sospecha de meningitis. *Consultas Medicas*. 1995;14(4):3-9.
10. Ahkee S, Srinath L, **Ramirez J.** Pseudomonas pickettii Pneumonia in a Diabetic Patient. *Journal of the Kentucky Medical Association*. 1995 Nov;93(11):511-3.
11. Tolentino A, Ahkee S, **Ramirez J.** Hot Tub Legionellosis. *Journal of the Kentucky Medical Association*. 1996 Sep;94:393-4.
12. **Ramirez J.** Cost Effectiveness of Treatment of Community-Acquired Pneumonia with Clarithromycin. *Infections in Medicine*. 1996; (Special Supplement):10-6.
13. Sarlo AJ, Miriucka SG, Moirano MM, **Ramirez JA.** Manejo de la profilaxis de infecciones en pacientes HIV positivos en el servicio de Enfermedades Infecciosas de la Universidad de Louisville. *Consultas Medicas*. 1996;17:25-32.
14. **Ramirez J, Cheadle WG.** Nosocomial Pneumonia in Patients Requiring Major Surgical Care. *Louisville Medicine*. 1996;44(4):151-4.
15. Tolentino A, Ahkee S, **Ramirez J.** Pancoast's Syndrome Secondary to Thoracic Actinomycosis. *Journal of the Kentucky Medical Association*. 1996;94(11):500-2.
16. Carrico R, **Ramirez J, Cheadle W.** Recommendations for Potential Occupational Exposure to HIV. *Louisville Medicine*. 1997;45(3):125-7.
17. Ahkee S, Srinath L, **Ramirez J.** Etiology of Community-Acquired Pneumonia. *VA Practitioner*. 1997;30-4.
18. Wojda B, Ahkee S, Uyamadu N, Jouja K, **Ramirez JA.** Tuberculosis in Kentucky: Current Recommendations for Empiric Therapy. *Journal of the Kentucky Medical Association*. 1997;95(3):99-101.
19. Snyder JW, **Ramirez JA.** Influencing Appropriate Utilization of Antibiotics in the Hospital Setting. *Clinical Microbiology Newsletter*. 1998;20:153-5. [https://doi.org/10.1016/S0196-4399\(00\)88649-3](https://doi.org/10.1016/S0196-4399(00)88649-3).

20. Gotfried M, Nightingale CH, **Ramirez J**. Emerging Issues in the Antimicrobial Treatment of Community-Acquired Pneumonia and the Acute Bacterial Exacerbations of Chronic Bronchitis. *Formulary*. 1998;33 S2:S36-S49.
21. **Ramirez JA**. Update in the Management of Community-Acquired Pneumonia. *Formulary*. 1998;33 S3:S34-S41.
22. **Ramirez JA**. Triple-Drug Combination Therapy for the Treatment of HIV Infection. *Louisville Medicine*. 1998;45(11):545-7.
23. Niederman MS, Weingarten SR, Corwin RW, Dean NC, Goldstein GE, Martinez F, **Ramirez JA**. Critical Decision in Respiratory Tract Infections: Principles for Switch Therapy and Early Discharge of Patients Hospitalized with Community-Acquired Pneumonia. A Continuing Medical Education Activity Sponsored by The University of Arizona College of Medicine at the Arizona Health Sciences Center published May, 1998.
24. **Ramirez, JA**, Nguyen T-H, Tellier G, Coppola G, Bettis RB, Dolmann A, St-Pierre C, Mayer H. Treating Community-Acquired Pneumonia with Once-Daily Gatifloxacin vs Twice-Daily Clarithromycin. *Journal of Respiratory Diseases*. 1999 Nov;20 11S:S40S48.
25. **Ramirez Julio**. Penicillin-Resistant Pneumococci: New-Generation Fluoroquinolones and Lower Respiratory Tract Infections. *Hospital Medicine*. 1999 Jun.
26. **Ramirez JA**. Challenges in the Management of Patients with Respiratory Tract Infections, Guest Editor's Note. *Bio Medicina*. 2000 Apr;3(4):150.
27. **Ramirez JA**. Management of the Patient with Upper Respiratory Tract Infection. *Bio Medicina* 2000 Apr;3(4):164-5.
28. **Ramirez JA**. Management of the Patient with Community-Acquired Pneumonia. *Bio Medicina* 2000 Apr;3(4):166-70.
29. **Ramirez JA**. Treatment of Community-Acquired Pneumonia: Role of the New Generation Quinolones. *Resident & Staff Physician*. 2001; (February):21-8.
30. **Ramirez JA**. Atypical Pneumonia. *Current Treatment Options in Infectious Diseases*. 2001;3:173-8.
31. **Ramirez, Julio**. Etiology of Community-Acquired Pneumonia: Emergence of Atypical Pathogens. *Community-Acquired Pneumonia: A Hospital Practice Special Report* 2000 Jun.
32. **Ramirez, Julio**. Managing Anti-infective Therapy of community-Acquired Pneumonia in the Hospital Setting: Focus on Switch Therapy. *Pharmacotherapy*. 2001 Jul;21 7,Part2:79S-82S. <https://doi.org/10.1592/phco.21.10.79S.34530>.
33. **Ramirez Julio A**, Tucker Richard M, Bettis Robert B, Cyganowski Marcia, Hunt Barbara J. Treating acute exacerbations of chronic bronchitis. *Journal of Respiratory Diseases* 2001 Aug. Supplement. S75-S80.
34. Schulz P, Allen M, Murray Q, Smith SA, Goss L, Carrico R, **Ramirez J**. Infections Due to Community-Acquired Methicillin Resistant Staphylococcus aureus: An Emergent Epidemic in Kentucky. *Journal of the Kentucky Medical Association*. 2005 May;103:194-203.
35. Peyrani P, Christensen D, LaJoie AS, Nakamatsu R, Arnold F, Schulz P, Toala I, Ramirez A, Lobo S, Johnson B, Chesnut D, Richmond B, De La Cruz R, Carrico R, **Ramirez J**; Community-Acquired Pneumonia Organization Investigators. Antibiotic therapy of hospitalized patients with community-acquired pneumonia: an international perspective from the CAPO Cohort Study. *Journal of the Kentucky Medical Association* 2006 Nov;104(11):513-7.

36. Arnold FW, Patel A, Nakamatsu R, Smith S, Newman D, Sciortino CV, Peyrani P, Snyder J, Schulz P, **Ramirez, JA**. Establishing a Hospital Program to Improve Antimicrobial Use, Control Bacterial Resistance and Contain Healthcare Costs: The University of Louisville Experience. *Journal of the Kentucky Medical Association* 2007 Sep;105:431-7.
37. **Ramirez JA**. RSV infection in the adult population. *Managing Care* 2008 Nov;17(11 Suppl 12):13-5, discussion 18-9.
38. Umoren I, Nakamatsu R, Sciortino C, Sarver J, Blake S, Peyrani P, Wiemken T, Woods C, **Ramirez J**. An Investigation of an Outbreak: Methicillin Resistant *Staphylococcus aureus* Colonization in an Intensive Care Cardiac Unit. *Journal of the Kentucky Medical Association*. 2009 Nov;107(11):443-9.
39. Wiemken T, Peyrani P, Carrico R, Kelley R, Heragu S, Jonnson C, Bryant K, Summersgill J, Arnold F, McKinney WP, **Ramirez J**, and the Influenza Clinical and Translational Research Program Investigators. Clinical and Translational Research in Influenza at the University of Louisville. *Journal of the Kentucky Medical Association*. 2012;110:149-56.
40. **Ramirez JA**. Clinical & Translational Research in Pneumonia: Defining a Research Agenda for Today and Tomorrow. *The University of Louisville Journal of Respiratory Infections*. 2017;1(2):1. <https://doi.org/10.18297/jri/vol1/iss2/1/>.
41. **Ramirez JA**. Pneumonia Research and the Omics Revolution: It is Time for PneumOmics. *The University of Louisville Journal of Respiratory Infections*. 2017;1(3):1. <https://doi.org/10.18297/jri/vol1/iss3/1/>.
42. **Ramirez JA**. Pneumonia Pathogenesis and the Lung Microbiome: Back to the Drawing Board. *The University of Louisville Journal of Respiratory Infections*. 2017;1(4):2. <https://doi.org/10.18297/jri/vol1/iss4/2/>.
43. **Ramirez JA**. Overview of community-acquired pneumonia in adults. UpToDate. 2018 Nov.
44. **Ramirez JA**. Clinical Research: From Idea to Publication. *Univ Louisville J Respir Infect*. 2018;2(1):12 <https://doi.org/10.18297/jri/vol2/iss1/12/>
45. **Ramirez JA**. A Continuum of Disease from Community-Acquired Pneumonia to Multiple Organ Dysfunction Syndrome. *Univ Louisville J Respir Infect*. 2018;2(2):1 <https://doi.org/10.18297/jri/vol2/iss2/1/>

ABSTRACTS

1. Contreras F, **Ramirez J**. "Respiratory Insufficiency in Patients with Myasthenia Gravis". Meeting of La Plata Medical Society. La Plata, Buenos Aires, Argentina. June 1980.
2. **Ramirez J**. "Arterial Hypoxemia due to Diuretics". Meeting of La Plata Medical Society. La Plata, Buenos Aires, Argentina. June 1980.
3. Moday M, **Ramirez J**, Najera R, et al. "Jaundice and Acute Abdomen at the End of Pregnancy". III Argentine Congress of Emergency Surgery. Buenos Aires, Argentina. March 1981.
4. Defelito J, **Ramirez J**, Cabral G, et al. "Early Signs of Post-Surgical Peritonitis". III Argentine Congress of Emergency Surgery. Buenos Aires, Argentina. March 1981.
5. **Ramirez J**. "Continuous Positive Airway Pressure (CPAP) in Adults through Facial Mask". Meeting of La Plata Medical Society. La Plata, Buenos Aires, Argentina. June 1982.
6. **Ramirez J**, Rivarola E. "Mixed Venous Acid-Base Determinations During CPR". Meeting of La Plata Medical Society. La Plata, Buenos Aires, Argentina. June 1983.
7. **Ramirez J**, Rivarola R. "New Cardiopulmonary Resuscitation, Our Experience". Meeting of La Plata Medical Society. La Plata, Buenos Aires, Argentina. November 1983.
8. **Ramirez J**, Summersgill J, Raff M. Comparative Bactericidal Activity of Ampicillin/Sulbactam and Erythromycin Against *Legionella pneumophila*. Fourth International Symposium on Legionella. Orlando, FL. January 1992.
9. Buster B, Powell L, **Ramirez J**, Miller R, Summersgill J. Role of Nitric Oxide in Killing of *Legionella pneumophila* in Gamma-Interferon Activated Macrophages. Fourth International Symposium on Legionella. Orlando, FL. January 1992.
10. **Ramirez J**, Summersgill J, Raff M. Frequency of Isolation and Antibiotic Susceptibility of 500 bacteria from the Respiratory Tracts of 500 Intensive Care Unit Patients. Interdisciplinary World Congress on Antimicrobial and Anticancer Drugs. Geneva, Switzerland. March, 1992.
11. **Ramirez J**, Summersgill J, Raff M. Bactericidal Activity of Imipenem Compared to Erythromycin Against Intracellular *Legionella pneumophila*. Interdisciplinary World Congress on Antimicrobial and Anticancer Drugs. Geneva, Switzerland. March, 1992.
12. **Ramirez J**, Raff M. Partial Resistance to Penicillin in Ten Cases of Streptococcus pneumoniae Infection in Louisville, Kentucky. 37th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY March, 1992.
13. **Ramirez J**, Raff M. Description and Control Measures to a Current Epidemic of TB Infection Among Health Care Workers. 37th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY March, 1992.
14. **Ramirez J**, Raff M. Treatment of community-Acquired Pneumonia in the Elderly with a Short Course of Ampicillin Sulbactam Followed by Oral Amoxicillin Clavulanate. American Society for Microbiology, 92nd General Meeting. New Orleans, LA. May, 1992.
15. Summersgill J, Powell L, Miller R. **Ramirez J**. Killing of *Legionella pneumophila* by Nitric Oxide Radicals in Gamma-Interferon Activated Macrophages. Society for Leukocyte Biology. 29th National Meeting. 1992.

16. Sahney N, Summersgill J, **Ramirez J**, Miller R. Effect of *Legionella pneumophila* Protease on Polymorphonuclear Leukocyte Surface Receptors. Society of Leukocyte Biology 29th National Meeting. Charleston, NC, 1992.
17. Ahkee S, **Ramirez J**, Srinath L, Huang A. Prospective Study of Cefizoxime in the Treatment of Community-Acquired Pneumonia. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
18. Srinath L, Ahkee S, Huang A **Ramirez J**. Acute Miliary. Blastomycosis in an HIV Infected Patient. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
19. Ahkee S, Srinath L, Huang A, Raff M, **Ramirez J**. Anaerobic Pulmonary Infection Secondary to Lemierre Syndrome. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
20. **Ramirez J**, Srinath L, Ahkee S, Huang A, Raff M. Community-Acquired Pneumonia: Incidence of *Legionella pneumophila* in Louisville, Kentucky. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
21. Srinath L, Ahkee S, Huang A, **Ramirez J**. Clinical and Laboratory Characteristics of Community-Acquired Pneumonia in the Elderly. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
22. Huang A, Srinath L, Ahkee S, **Ramirez J**. Tuberculosis Presenting as Acute Community-Acquired Pneumonia. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
23. Huang A, Ahkee S, Srinath L, **Ramirez J**. Incidence and Resistant Patterns of Multi-Drug Resistant Tuberculosis in Jefferson County, Kentucky. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
24. **Ramirez J**, Anderson P, Herp S, Fyfe V. Mycobacterium other than Tuberculosis at a University Hospital. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
25. **Ramirez J**, Anderson P, Herp S, Fyfe V. Nasal Intubation: Risk Factor for Ventilator Associated Pneumonia. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
26. **Ramirez J**, Herp S, Anderson P, Fyfe V. Frequency of Tuberculosis with Negative Sputum Smear for Acid-Fast Organisms at a University Hospital. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
27. Ahkee S, Herp S, Fyfe V, **Ramirez J**. Tuberculosis Presenting as Nosocomial Pneumonia. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
28. **Ramirez J**, Srinath L, Ahkee S, Huang A, Raff M. HIV Negative "AIDS" in Kentucky: A Case of Idiopathic CD4 Lymphopenia and Cryptococcal Meningitis. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
29. **Ramirez J**, Summersgill J, Raff M. Optimal Empiric antibiotics for Treatment of Intensive Care Unit Acquired Pneumonia in Louisville, Kentucky. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.

30. **Ramirez J**, Summersgill J, Greenburg L. New Rapid Tests for the Diagnosis of Legionnaires' Disease. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
31. Miller R, Sahney N, Summersgill J, **Ramirez J**. Isolation and Elimination of *Legionella pneumophila* from the hospital water supply. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
32. Buck G, Sahney N, Summersgill J, Miller R, **Ramirez J**. Use of Polymerase Chain Reaction (PCR) for Diagnosing *Mycoplasma pneumoniae* Infections. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
33. **Ramirez J**, Burke J, Ritter B. Switch Therapy for the Treatment of Community-Acquired Pneumonia (CAP). 38th Annual Kentucky Thoracic society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
34. Sahney N, Summersgill J, Miller R, Buck G, **Ramirez J**. Diagnosis of *Legionella* pulmonary infections by polymerase chain reaction (PCR). 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, KY. March, 1993.
35. Buck G, Sahney N, Summersgill J, Miller R, **Ramirez J**. Use of Polymerase Chain Reaction (PCR) for Diagnosing *Mycoplasma pneumoniae* Pneumonia. American Society for Microbiology Annual Meeting. 1993.
36. **Ramirez J**, Sahney N, Summersgill J, Miller R. Comparative Bactericidal Activity of Ticarcillin/clavulanic acid and Erythromycin Against Intracellular *Legionella pneumophila*. 18th International Congress of Chemotherapy. Stockholm, Sweden. June, 1993.
37. **Ramirez J**, Srinath L, Ahkee S, Huang A, Raff M. Community-Acquired Pneumonia in the Elderly, Clinical Features. 18th International Congress of Chemotherapy. Stockholm, Sweden. June, 1993.
38. **Ramirez J**, Srinath L, Ahkee S, Raff M. Switch Therapy with Oral Cefixime After Intravenous Third Generation Cephalosporins for the Treatment of Community-Acquired Pneumonia. 19th International Congress of Chemotherapy. Stockholm, Sweden. June, 1993.
39. **Ramirez J**, Srinath L, Ahkee S, Raff M. Incidence of Legionella Community-Acquired Pneumonia in Louisville, Kentucky. 18th International Congress of Chemotherapy. Stockholm, Sweden. June, 1993.
40. Summersgill J, Sahney N, Greenburg L, Miller R, Buck G, **Ramirez J**. Polymerase Chain Reaction (PCR) Compared with Direct Fluorescent Antibody and Culture for the Detection of *Legionella pneumophila* in Bronchoalveolar Lavage Fluid. 18th International Congress of Chemotherapy. Stockholm, Sweden. June, 1993.
41. **Ramirez J**, Burke J, Ritter B, Smith S, Newman D. A Switch Therapy Program for Antimicrobial Agents: Development and Implementation. Annual Meeting of the American College of Clinical Pharmacy. San Diego, CA. January, 1994.
42. Srinath L, Ahkee S, Tolentino A, Bocado C, **Ramirez J**. Atypical Presentation of Community-Acquired Pneumonia in the Elderly is Associated with Increased Mortality. 39th Annual Kentucky Thoracic society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
43. Tolentino A, Ahkee S, Srinath L, **Ramirez J**. Incidence of Unrecognized Lung Carcinoma in Elderly Patients Admitted to Hospital with Community-Acquired Pneumonia. 39th Annual

- Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
44. Tolentino A, Ahkee S, Srinath L, **Ramirez J**. Association of *Hemophilus influenza* with Multilobar Community-Acquired Pneumonia in the Elderly. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
 45. Kromer E, Summersgill J, **Ramirez J**. Improved Detection of *Chlamydia pneumoniae* in Bronchoalveolar lavage Fluid Specimens by Polymerase Chain Reaction. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
 46. Ahkee S, Srinath L, Tolentino A, Siddiqui S, **Ramirez J**. Community-Acquired Pneumonia of Unknown Etiology in Louisville. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
 47. Ahkee S, Srinath L, Tolentino A, Siddiqui S, **Ramirez J**. Decreasing Incidence of *streptococcus pneumonia* Community-Acquired Pneumonia in Louisville. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
 48. **Ramirez J**, Molestina R, Sahney N, Greenburg L, Summersgill J. Polymerase Chain Reaction on Throat Swab is More Sensitive than Acute Serology for the Diagnosis of *Mycoplasma pneumoniae* Respiratory Infections. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY March, 1994.
 49. Ahkee S, Srinath L, Tolentino A, Sciortino C, **Ramirez J**. *Pseudomonas picketti* Pneumonia in a Diabetic Patient. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
 50. Burke J, Ritter G, Smith S, Newman D, Bocado C, Ramos F, **Ramirez J**. Economic Impact of Switch Therapy Based on Length of Hospital Stay for Pneumonia Patients at the VA Medical Center of Louisville. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
 51. Ahkee S, Smith R, Ritter G, Srinath L, Tolentino A, **Ramirez J**. Once Daily Dosing of Aminoglycosides in Severe Lower Respiratory Tract Infections. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
 52. Neuman D, Smith S, Bocado C, Ramos F, Ritter G, Burke J, **Ramirez J**. Drug Cost-Saving Analysis of Lower Respiratory Tract Infections Treated with Switch Therapy. 39th Annual Kentucky Thoracic Society Scientific conference on Pulmonary Disease. Lexington, KY. March, 1994.
 53. Smith S, Neuman D, Bocado C, Ramos F, Ritter G, Burke J, **Ramirez J**. Experience with Switch Therapy in the Management of Hospitalized Patients with Pneumonia. 39th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Lexington, KY. March, 1994.
 54. Sahney N, **Ramirez J**, Greenburg L, Miller R, Summersgill J. Inhibition of *Chlamydiae pneumoniae* Replication in HEp2 Cells by Gamma Interferon. 94th General Meeting of the American Society for Microbiology. Las Vegas. May, 1994.
 55. Gaydos C, Summersgill J, Sahney N, **Ramirez J**, Quinn T. *Chlamydia pneumoniae* is Capable of Growing in Smooth Muscle Cells of Aortic Origin in Tissue Culture. 94th General Meeting of the American Society for Microbiology. Las Vegas. May, 1994.

56. **Ramirez J**, Sahney N, Ahkee S, Miller R, Summersgill J. Rapid Diagnosis of Legionnaires Disease by DNA Amplification of Throat Swab Specimens. American Society for Microbiology. Las Vegas. May, 1994.
57. Summersgill J, Gaydos C, Quinn T, Fowler C, **Ramirez J**. Detection of Legionella in an Immunocompromised Population with Pneumonia Using the Polymerase Chain Reaction. American Society for Microbiology. Las Vegas. May, 1994.
58. Summersgill J, Schmidt E, Gaydos C, Sahney N, Quinn T, **Ramirez J**. Replication of *Chlamydia pneumoniae* in Human Pulmonary Artery Endothelial Cells. American Society for Microbiology. Las Vegas. May, 1994.
59. **Ramirez J**, Sahney N, Miller R, Summersgill J. Activity of Erythromycin, Rifampin, Ciprofloxacin, and Ofloxacin Alone or in Combination Against Intracellular *Legionella pneumophila*. American Society for Microbiology. Las Vegas. May, 1994.
60. Sahney N, **Ramirez J**, Summersgill J, Miller R. Degradation and Inactivation of Human Cytokines by *Legionella pneumophila* Protease. American Society for Microbiology. Las Vegas. May, 1994.
61. Zhang Y, Powell L, Tse P. Justus D. Summersgill J, **Ramirez J**, Miller R. Characterization of *Legionella pneumophila* Replication in Human Pulmonary and Umbilical Endothelial Cells. American Society for Microbiology. Las Vegas. May, 1994.
62. Gaydos C, Summersgill J, Sahney N, **Ramirez J**, Quinn T. Growth Characteristics of *Chlamydiae pneumoniae* in Macrophages and Endothelial Cells. Eighth International Symposium on Human Chlamydial Infections. Chateau de Montvillargenne, Chantilly, France. June, 1994.
63. Summersgill J, Gaydos C, Schmidt E, Sahney N, Quinn T, **Ramirez J**. Replication of *Chlamydiae pneumoniae* in Human Endothelial Cells of Various Origin. Eighth International symposium on Human Chlamydial Infections. Chateau de Montvillargenne, Chantilly, France. June, 1994.
64. Tolentino A, Ahkee S, **Ramirez J**. Pancoast's syndrome secondary to thoracic actinomycosis. 40th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Poster presentation)
65. Tolentino A, Ahkee S, **Ramirez J**. Risk factors for multi-drug resistant tuberculosis in Kentucky. 40th Annual Kentucky Thoracic Society Scientific Conference n Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Oral presentation)
66. Uyamadu N, Ahkee S, **Ramirez J**. Impact of mandatory respiratory isolation of patients with community-acquired pneumonia on an epidemic of *Mycobacterium tuberculosis* infection among workers at the University of Louisville Hospital. 40th Annual Kentucky Thoracic Society Scientific Conference n Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Oral presentation)
67. Uyamadu N, Ahkee S, **Ramirez J**. A case of *Pneumocystis carinii* pneumonia in an immunocompetent host. 40th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Poster presentation)
68. Uyamadu N, Ahkee S, **Ramirez J**. Radiologic finding in Legionnaire's disease. 40th Annual Kentucky Thoracic Society Scientific conference on Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Poster presentation)

69. Wojda B, Ahkee S, **Ramirez J**. *Mycobacterium tuberculosis* susceptibility in Kentucky: current recommendations for empiric therapy. 40th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Oral presentation)
70. Summersgill J, Ahkee S, **Ramirez J**. *Chlamydia pneumoniae*: a pulmonary pathogen associated with atherosclerosis. 40th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Oral presentation)
71. Ahmad A, Ahkee S, **Ramirez J**. The radiographic resolution of community-acquired pneumonia in the elderly. 40th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Poster presentation)
72. Hamad A, Ahkee S, **Ramirez J**. Correlation of Gram stain and sputum culture with etiology of community-acquired pneumonia. 40th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Poster presentation)
73. **Ramirez J**, Ahkee S, Tolentino A, Summersgill J. Diagnosis of *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and *legionella pneumophila* lower respiratory infections using polymerase chain reaction on a single throat swab specimen. 40th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease. Louisville, Kentucky. March 17-18, 1995. (Poster presentation)
74. Ahkee S, Barzallo M, **Ramirez J**. Empiric antibiotic therapy in patients without documented infections. Infectious Diseases Society of America meeting. San Francisco, California. September 16, 1995. (Poster presentation)
75. Uyamadu N, Ahkee S, **Ramirez J**. Resolution of an epidemic of *Mycobacterium tuberculosis* infection among workers at a University Hospital after mandatory respiratory isolation of patients with community-acquired pneumonia. Infectious Diseases Society of America meeting. San Francisco, California. September 16, 1995. (Poster presentation)
76. Ahkee S, **Ramirez J**. Cost savings resulting from early switch to oral cefixime in the treatment of hospitalized patients with community-acquired pneumonia. Infectious Diseases Society of American meeting. San Francisco, California. September 16, 1995. (Poster presentation)
77. **Ramirez J**, Ahkee S, Ganzel B, Ogden L, Gaydos C, Quinn T, Hammerschlag M, Roblin P, LeBar W, Kuo C, Campbell L, Grayston J, Patton D, Dean D, Schraeter J, Summersgill J. Isolation of *Chlamydia pneumoniae* from the coronary artery of a patient with coronary atherosclerosis. ICAAC meeting. San Francisco, California. September 20, 1995. (Poster presentation)
78. Ahkee S, **Ramirez J**. *Legionella pneumophila* and *Streptococcus pneumoniae* as co-pathogens in community-acquired pneumonia: case reports in 2 young adults. 41st Annual Kentucky Thoracic Society Scientific Conference on Lung Disease. Lexington, Kentucky. March 8-9, 1996. (Poster presentation)
79. Jouja K, Ahkee S, Wojda B, Uyamadu N, **Ramirez J**. Acute lobar community-acquired pneumonia in an elderly patient caused by *Mycobacterium tuberculosis*. 41st Annual Kentucky Thoracic Society Scientific Conference on Lung Disease. Lexington, Kentucky. March 8-9, 1996. (Poster presentation)
80. Jouja K, Ahkee S, Wojda B, Uyamadu N, **Ramirez J**. Cavitary pneumonia in an AIDS patient caused by *Rhodococcus equi*: case report. 41st Annual Kentucky Thoracic Society Scientific Conference on Lung Disease. Lexington, Kentucky. March 8-9, 1996. (Poster presentation)

81. Wojda B, Ahkee S, Jouja K, Uyamadu N, **Ramirez J**. Tuberculosis in Kentucky: current recommendations for empiric therapy. 41st Annual Kentucky Thoracic Society Scientific Conference on Lung Disease. Lexington, Kentucky. March 8-9, 1996. (Oral presentation)
82. Uyamadu N, Ahkee S, Jouja K, Wojda B, **Ramirez J**. Switch Therapy: patient outcomes and savings in nosocomial pneumonia. 41st Annual Kentucky Thoracic Society Scientific Conference on Lung Disease. Lexington, Kentucky. March 8-9, 1996. (Oral presentation)
83. **Ramirez J**, Ahkee S, Kitay M, Miller R, Summersgill J. Diagnosis of Legionnaires Disease: PCR amplification of the 5S rRNA of *Legionella* in urine and serum samples. Annual Infectious Diseases Society of America Meeting. San Francisco, CA. September 13-16, 1997.
84. **Ramirez J**, Vargas J, Bordon J, Ahkee S. Clinical Outcome of Hospitalized Patients with Community-Acquired Pneumonia (CAP) when the Switch from IV to Oral Antibiotics is Performed at the Point of Clinical Stability. Annual Infectious Diseases Society of America Meeting. San Francisco, CA. September 13-16, 1997.
85. **Ramirez J**. A Comparative Study of Sparfloxacin (SPAR) and Clarithromycin (CLAR) in the Treatment of Outpatients with Community-Acquired Pneumonia (CAP). Annual Infectious Diseases Society of America Meeting. San Francisco, CA. September 13-16, 1997.
86. **Ramirez J**, Ahkee S, Kitay M, Miller R, Pinar A, Summersgill J. Legionnaires Disease Acquired from a Malfunctioning Automobile Air Conditioner. Annual Infectious Diseases Society of America Meeting. San Francisco, CA. September 13-16, 1997.
87. Bordon J, Vargas J, Ahkee S, **Ramirez J**. Early Switch from Intravenous (IV) to Oral Antibiotics in Patients with Bacteremic *Streptococcus pneumoniae* (Sp) Community-Acquired Pneumonia (CAP). Annual Infectious Diseases Society of America Meeting. San Francisco, CA. September 13-16, 1997.
88. Vargas J, Bordon J, Ahkee S, **Ramirez J**. Factors That Interfere with Hospital Discharge in Patients with Community-Acquired Pneumonia (CAP) After They Reach Clinical Stability. Annual Infectious Diseases Society of America Meeting. San Francisco, CA. September 13-16, 1997.
89. Schwartz DB, Sherman BW, Gezon JA, Wishnow RM, Arnow PM, Suh B, **Ramirez JA**, Barone J, Kolokathis A. Safety and Efficacy of Intravenous and Oral Azithromycin for the Treatment of Patients with Community-Acquired Pneumonia (CAP). American Society for Microbiology. Atlanta, GA. May, 1998.
90. Molestina RE, Miller RD, Summersgill JT, **Ramirez JA**. Proc. Ninth Int'l. Symp. On Human Chlamydial Infection. Napa, CA, p. 419, 1998.
91. Uriarte SM, Molestina RE, Miller RD, **Ramirez JA**, Summersgill JT. Migration of human monocytes through *Chlamydia pneumoniae*-infected endothelial cells: effects of roxithromycin. Abst. Inersc. Conf. Antimicrob. Agents Chemother., #981, p. 669, 1999.
92. Molestina RE, Summersgill JT, Miller RD, **Ramirez JA**. Expression of monocyte chemotactic protein-1 mRNA in human endothelial cells infected with *Chlamydia pneumoniae*. Abst. Annual Meeting American Society for Microbiology. D/B-78, p. 224, 1999.
93. Summersgill JT, **Ramirez JA**, Conetta B, Mayer HB. Importance of Atypical Pathogens as Single or Combined Etiology of Community-Acquired Pneumonia (CAP). Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September, 1999. (Slide presentation)

94. **Ramirez J**, Nguyen TH, Tellier G, Coppola G, Bettis R, Dolmann A, St-Pierre C, Mayer H. Once-Daily 400mg oral Gatifloxacin (GAT) vs Twice-Daily 500mg Oral Clarithromycin (CLA) in the Treatment of Community-Acquired Pneumonia (CAP). Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September, 1999. (Poster presentation)
95. **Ramirez JA**, Summersgill JT, Anderson A, Conetta B, Mayer H. Community-Acquired Pneumonia Involving Atypical Pathogens Treated with Gatifloxacin vs Ceftriaxone ± Erythromycin, Clarithromycin or Levofloxacin. Infectious Diseases Society of America. Philadelphia, PA. November, 1999. (Poster presentation)
96. Pantoja LG, Miller RD, Summersgill JT, **Ramirez JA**. Inhibition of *Chlamydia pneumoniae* replication in IFN-gamma-stimulated aortic smooth muscle cells. Abst. Annual Meeting American Society for Microbiology D-78, p. 243, 2000.
97. **Ramirez JA**. Switch Therapy: Cost Effectiveness Issue. 9th International Congress on Infectious Diseases. Buenos Aires, Argentina. April, 2000. (Slide presentation)
98. **Ramirez JA**, Cohen G., Summersgill JT. Etiology in Community-Acquired Pneumonia: Incidence of Combined Typical and Atypical Pathogens. Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA September, 2000. (Poster presentation)
99. **Ramirez JA**, Cohen G., Summersgill JT. Atypical Pathogens Causing Community-Acquired Pneumonia (CAP): Presumptive vs Definitive Etiology. Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA September, 2000. (Poster presentation)
100. Uriarte SM, Molestina RE, Miller RD, Farinati A, Eiguchi K, **Ramirez JA**, Summersgill JT. Effects of macrolide antibiotics on the migration of human monocytes through *Chlamydia pneumoniae*-infected cells. Poster D-212, abstract GM01-a-34762-ASM. 101st General Meeting American Society for Microbiology. Orlando, FL. May, 2001.
101. **Ramirez J**, Magar NA, Christensen D, Dobbs S, Carrico R, McDonald LC, Xia L. Implementation of Infection-Specific Antibiotic Guidelines: What is Next after Community-Acquired Pneumonia?. Poster K-1197, 41st International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. Sept. 22-25, 2001. (Poster)
102. Christensen D, Magar NA, Dobbs S, Carrico R, McDonald LC, Xia L, **Ramirez J**. The Incremental Benefit of Antimicrobial Team Interventions over Dissemination of Guidelines of Order Forms to Reach an Acceptable Level of Inappropriate Vancomycin Use. Poster K-1196, 41st International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. Sept. 22-25, 2001. (Poster)
103. Nair S, Christensen D, **Ramirez J**. The Clinical Outcome of Hospitalized Patients with Community-Acquired Pneumonia (CAP): Clinical Improvement, Clinical Failure, and Non-resolving Pneumonia. Poster, Research Louisville. Louisville, KY. October 30, 2001. (Poster)
104. Puranam P, Christensen D, Mallampalli A, Guardioli J, McDonald C, Xia L, **Ramirez JA**. Lack of Clinical Response in Hospitalized Patients with Community-Acquired Pneumonia Who are Treated with Empiric Therapy According to National Guidelines is Seldom due to Inadequate Antimicrobial Coverage. 39th Meeting of the Infectious Diseases Society of America. San

Francisco, CA. October 26, 2001. (Slide)

105. Chagua MR, McDonald C, **Ramirez JA**, Xia L. Limitation of the Pneumonia Severity Index as a Tool to Evaluate Inappropriateness of Hospitalization among Patients with Community-Acquired Pneumonia. 39th Meeting of the Infectious Diseases Society of America. San Francisco, CA. October 26, 2001. (Poster)
106. Nakamatsu R, Magar NA, McDonald LC, Xia L, **Ramirez JA**. Evaluating the Appropriateness of Empiric Antibiotic Therapy in Hospitalized Patients with Community-Acquired Pneumonia: The Right Drug, the Right Dose, at the Right Time. 39th Meeting of the Infectious Diseases Society of America. San Francisco, CA. October 26, 2001. (Poster)
107. Oshiro H, McDonald C, **Ramirez JA**. Appropriate Evaluation of Tuberculosis Control Policies: Looking beyond the Initiation of Respiratory Isolation. 39th Meeting of the Infectious Diseases Society of America. San Francisco, CA. October 26, 2001. (Poster)
108. Arnold F, **Ramirez JA**. Development of Handheld Computer Software to Assist in Antimicrobial Evaluation and Generation of Customized Feedback. 39th Meeting of the Infectious Diseases Society of America. San Francisco, CA. October, 2002. (Poster)
109. Arnold F, **Ramirez JA**. Use of a Handheld Computer Program to Compare the Appropriateness of Hospital Antimicrobial use Between Medical and Surgical Specialties. 39th Meeting of the Infectious Diseases Society of America. San Francisco, CA. October, 2002. (Poster)
110. Nakamatsu R, **Ramirez JA**. Switch Therapy in Hospitalized Patients with Skin and Soft Tissue Infections. 39th Meeting of the Infectious Diseases Society of America. San Francisco, CA. October, 2002. (Poster)
111. Christensen D, Newman D, Smith R, **Ramirez JA**, Xia L. Time to Clinical Stability and Switch Therapy in Hospitalized Patients with Pyelonephritis. 39th Meeting of the Infectious Diseases Society of America. San Francisco, CA. October, 2002. (Poster)
112. **Ramirez JA**, McDonald C, Bouzon SC, Ritter G, Newman D, Smith S, Xia L. Improving Antimicrobial Use in Hospitalized Patients: The Long Term Impact of an Antimicrobial Team. 39th Meeting of the Infectious Diseases Society of America. San Francisco, CA. October, 2002. (Poster)
113. Arnold F, Jain S, Christensen D, **Ramirez JA**, and the Community -Acquired Pneumonia Organization Investigators. Pneumonia-Related versus Pneumonia-Unrelated Length of Stay in Hospitalized Patients with Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 99th International Meeting of the American Thoracic Society. Seattle, WA. May 19, 2003. (Poster)
114. Jain S, Smith S, Hart S, Christensen D, **Ramirez JA**, and the Community -Acquired Pneumonia Organization Investigators. Candidates for Pathogen Directed Therapy in Hospitalized Patients with Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 99th International Meeting of the American Thoracic Society. Seattle, WA. May 20, 2003. (Poster)
115. Nakamatsu R, Newman D, Hart S, Christensen D, **Ramirez JA**, and the Community -Acquired Pneumonia Organization Investigators. Time to Clinical Stability and Switch Therapy in Hospitalized Patients with Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 99th International Meeting of the American

Thoracic Society. Seattle, WA. May 19, 2003. (Poster)

116. Christensen D, Xia E, Anjum R, Goyal P, McDonald C, **Ramirez JA**, and the Community - Acquired Pneumonia Organization Investigators. How common are Risk Factors for Tuberculosis in Hospitalized Patients with Pneumonia? Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 99th International Meeting of the American Thoracic Society. Seattle, WA. May 19, 2003. (Poster)
117. Christensen D, McDonald C, Xia E, Carrico R, **Ramirez JA**, and the Community -Acquired Pneumonia Organization Investigators. Defining Risk Factors for Tuberculosis in Hospitalized Patients with Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 99th International Meeting of the American Thoracic Society. Seattle, WA. May 20, 2003. (Poster)
118. **Ramirez, JA**. International Approaches to Community-Acquired Pneumonia. 99th International Meeting of the American Thoracic Society. Seattle, WA. May 21, 2003. (Oral)
119. **Ramirez, JA**. Internet Based International Research in Community-Acquired Pneumonia: The Community-Acquired Pneumonia Organization (CAPO) Project. International Society of Chemotherapy Community-Acquired Pneumonia Conference. Ontario, Canada. September 11, 2003. (Poster)
120. Christensen D, Gross P, Legnani D, Martinez J, Bodi M, **Ramirez J**. Strategies to Prevent Pneumonia are Used Infrequently in Hospitalized Patients with Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 100th International Meeting of the American Thoracic Society. Orlando, FL. May 25, 2004. (Poster).
121. Christensen D, Feldman C, Blasi F, Levy G, Lode H, **Ramirez J**. The Presence of HIV Infection Does Not Influence Clinical Outcomes in Hospitalized Patients with Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 100th International Meeting of the American Thoracic Society. Orlando, FL. May 25, 2004. (Poster).
122. Arnold F, Blasi F, Roig J, Mateo M, Corral J, **Ramirez J**. Empiric Antibiotic Therapy with Coverage for Atypical Pathogens is Associated with Better Outcomes in Hospitalized Patients with Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 100th International Meeting of the American Thoracic Society. Orlando, FL. May 23, 2004. (Poster).
123. Khanzada Z, Rodriguez E, Cosentini R, Parada M, Benchetrit G, **Ramirez J**. Discrepancies between Physicians' Clinical Diagnosis of Community-Acquired Pneumonia and Diagnosis Based on Objective Criteria: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 100th International Meeting of the American Thoracic Society. Orlando, FL. May 25, 2004. (Poster).
124. De la Cruz R, Marrie T, Fernandez P, File T, Porras J, **Ramirez J**. Association of Initial Empiric Antibiotic Therapy with length of Stay and Mortality in Hospitalized Patients with Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 100th International Meeting of the American Thoracic Society. Orlando, FL. May 23, 2004. (Poster).

125. De la Cruz R, Rossi P, Weiss K, File T, Marrie T, **Ramirez J.** Empiric Antibiotic Therapy with Quinolones in Hospitalized Patients with Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 100th International Meeting of the American Thoracic Society. Orlando, FL. May 23, 2004. (Poster).
126. Nakamatsu R, Luna CM, Arteta F, Mendoza M, Torres A, **Ramirez J.** COPD is not a Risk Factor for Poor Clinical Outcomes in Hospitalized Patients with Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. 100th International Meeting of the American Thoracic Society. Orlando, FL. May 25, 2004. (Poster).
127. Christensen D, De la Cruz R, Levy G, Rodríguez E, Díaz Fuenzalida A, Bodi, Parada M, and **Ramírez J.** Bacteremic community-acquired pneumonia: The importance of *Staphylococcus aureus*. Results from the community-acquired pneumonia organization (CAPO) international cohort study [abstract 3062]. In Respiratory and critical care medicine: abstracts from 2005 International American Thoracic Society Conference. California: American Thoracic Society; 2005. p. A173. (poster)
128. De la Cruz R, Christensen D, Martinez J, Gross P, Arteta F, Cosentini R, Lode H, Luna J, and **Ramirez J.** Hospitalized patients with community-acquired pneumonia do not benefit from continuing intravenous antibiotics after reaching clinical stability: results from the community-acquired pneumonia organization (CAPO) international cohort study [abstract 3880]. In Respiratory and critical care medicine: abstracts from 2005 International American Thoracic Society Conference. California: American Thoracic Society; 2005. p. A47. (poster)
129. Arnold FW, Summersgill JT, Blasi F, File T, Fernandez P, Porras J, Feldman C, and **Ramirez JA.** Community-acquired pneumonia due to atypical pathogens: a worldwide comparison of the incidence and initial empiric therapy. Results from the community-acquired pneumonia organization (CAPO) international cohort study [abstract 3850]. In Respiratory and critical care medicine: abstracts from 2005 International American Thoracic Society Conference. California: American Thoracic Society; 2005. p. A46. (poster)
130. Peyrani P, De la Cruz R, Luna C, Marrie T, Rello J, Benchetrit G, Menendez R, and **Ramirez J.** Outcomes associated with monotherapy versus combination therapy in hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization (CAPO) international cohort study [C 86]. In Respiratory and critical care medicine: abstracts from 2005 International American Thoracic Society Conference. California: American Thoracic Society; 2005. p. A798. (poster)
131. Peyrani P, Weiss K, Legnani D, Mendoza R, Roig J, Corral J, Torres A, Mateo M, and **Ramirez J.** Hospitalized patients with community-acquired pneumonia do not benefit from in-hospital observation after switch therapy is performed: results from the community-acquired pneumonia organization (CAPO) international cohort study [C 86]. In Respiratory and critical care medicine: abstracts from 2005 International American Thoracic Society Conference. California: American Thoracic Society; 2005. p. A798. (poster)
132. Christensen D., Luna CM., Martinez J., Rodriguez E., Marzoratti L., Gonzalez J., Videla A., de Vedia L., Corral J., Benchetrit G., Rodriguez M., Peyrani P., **Ramirez J.** Compliance with National Guidelines for the Management of Hospitalized Patients with Community-Acquired

- Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. ATS 2006 San Diego, CA, May 19-24, 2006. [Publication Page: A150]
133. Peyrani P., Blasi F., Levy G., Lode H., Roig J., Bodi M., **Ramirez J.** Using Time to Clinical Stability to Define Duration of Therapy in Hospitalized Patients with Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. ATS 2006 San Diego, CA, May 19-24, 2006. [Publication Page: A151]
 134. Restrepo MI., Mortensen EM., Anzuelo A., Peyrani P., **Ramirez J.** Performing Blood Cultures is not Associated with Decreased Mortality in Hospitalized Patients with Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. ATS 2006 San Diego, CA, May 19-24, 2006. [Publication Page: A402]
 135. Chesnut D., Peyrani P., Toala I., LaJoie S., Nakamatsu R., Arnold F., **Ramirez J.** Duration of therapy in hospitalized patients with Community-Acquired Pneumonia: An International Perspective from the Community-Acquired Pneumonia Organization (CAPO) Cohort Study. ATS 2006 San Diego, CA, May 19-24, 2006. [Publication Page: A151]
 136. Rossi P., Selmo V., Bais B., Udina P., **Ramirez J.**, CAPO Investigators. Role of Age in Providing Intensive Care to Very Elderly Patients Hospitalized Patients with Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. ATS 2006 San Diego, CA, May 19-24, 2006. [Publication Page: A298]
 137. Rossi P., Selmo V., Bais B., Schiavon I., **Ramirez J.**, CAPO Investigators. Clinical Efficacy of Switch Therapy in Very Elderly Patients Hospitalized with Community Acquired Pneumonia: Results from the Community Acquired Pneumonia Organization (CAPO) International Cohort Study. ATS 2006 San Diego, CA, May 19-24, 2006. [Publication Page: A149]
 138. Allen M., Tobbe K., Peyrani P., Lett P., Malinis M., Myers J., **Ramirez J.** Predicting Methicillin-Resistant *Staphylococcus aureus* as the Etiology of Community-Acquired Pneumonia in Hospitalized Patients. Research!Louisville 2006. October, 10-13, 2006. (Poster presentation).
 139. Lett P, Peyrani P, Allen M, Malinis M, Meyers J, **Ramirez J.** Chest X-ray Findings in Patients with Community-Acquired Pneumonia due to Tuberculosis. Results from the Community Acquired Pneumonia Organization (CAPO) International Cohort Study. Research!Louisville 2006. October, 10-13, 2006. (Poster presentation).
 140. Malinis M, Kobbe K, Peyrani P, Lett P, Allen M, Myers J, **Ramirez J.** Presence of HIV Infection does not Influence Outcomes of Hospitalized Patients with Bacterial Community-Acquired Pneumonia: Results from the Community-Acquired Pneumonia (CAPO) Organization Internal Cohort Study. Research!Louisville 2006. October, 10-13, 2006. (Poster presentation).
 141. Allen M., MD, Toala I., MD, Herrera N., MD, Newman D., Rph, Johnson B., MD, Peryrani, P., MD, Nakamatsu R., MD. LaJoie S., PhD, Schulz P., MD, **Ramirez J., MD.** The Role of Erythrocyte Sedimentation Rate in the Follow-up of Patients with Osteomyelitis. Research!Louisville 2006. October, 11-14, 2006. (Poster presentation).
 142. Maria Tillan, MD, Norky Herrera, MD, Ivan Toala, MD, Paula Peyrani, MD, Marty Allen, MD, Scott Smith, Rph, David Newman, Rph, Scott Lajoie, PhD, Paul Schulz, MD, **Julio Ramirez,**

- MD.** Clinical Outcomes in Patients with Osteomyelitis.. Research!Louisville 2006. October, 11-14, 2006. (Poster presentation).
143. M. Allen, P. Peryani, F. Arnold, N. Haque, M. Zervos and **J. Ramirez**. Incidence of Panton-Valentin Leukocidin gene in Methicillin Resistant *Staphylococcus aureus* (MRSA) Isolates from Patients who Died due to MRSA Hospital-Acquired Pneumonia. American Thoracic Society. San Francisco, California. May 19-23, 2007.
 144. M. Allen, P. Peyrani, J. Myers, R. Cosentini, J. Martinez, M. Restrepo, **J. Ramirez** and the CAPO Investigators. Lack of Risk Factors for Methicillin Resistant *Staphylococcus aureus* in Hospitalized Patients with Community-Acquired Pneumonia due to MRSA: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. American Thoracic Society. San Francisco, California. May 19-23, 2007.
 145. P. Peyrani, M. Allen, R. Nakamatsu, and **J. Ramirez**. The Role of Tigecycline in the in the Treatment of Infections due to Extreme-Drug Resistant *Acinetobacter baumannii*: Report of 25 Cases. American Thoracic Society. San Francisco, California. May 19-23, 2007.
 146. Marty Allen, Pauline Lett, Stefano Aliberti, Fidaa Shaib, Marcus Zervos, and **Julio Ramirez**. Clinical Outcomes of Patients with Hospital-Acquired Pneumonia due to Community-Associated Methicillin Resistant *Staphylococcus aureus* (CA-MRSA). European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
 147. S. Aliberti, A. Amir, G. N. Brock, B. K. Moffett, P. Peyrani, M. Volpi, F. Blasi, **J. A. Ramirez**. Physician should not use the pneumonia severity index (psi) or crb-65 in deciding the need for hospitalization in cancer patients with community-acquired pneumonia (CAP). European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
 148. P. Fernandez, P. Jimenez, P. Peyrani, **J. Ramirez**. The presence of diabetes does not influence clinical outcomes in patients with community-acquired pneumonia: results from the community-acquired pneumonia organization (capo) international cohort study. European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
 149. A. Amir, S. Aliberti, P. Peyrani, F. Arnold, M. Cirino, **J. Ramirez**. Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP). European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
 150. J. Bordon, P. Peyrani, G. Brock, **J. Ramirez**. Mortality directly related to community-acquired pneumonia (cap) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study. European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
 151. J. Summersgill, **J. Ramirez**. Antimicrobial susceptibility of atypical pathogens. European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
 152. P. Lett, A. Amir, S. Aliberti, P. Peyrani, **J. Ramirez**. How often can we use short course therapy in patients with hospital-acquired pneumonia? European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
 153. P. Peyrani, A. Amir, M. F. Malinis, M. Cirino, R. Nakamatsu, **J. A. Ramirez**. Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia. European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.

154. F. Arnold, T. Wiemken, P. Peyrani, R. Nakamatsu, P. Lett, **J. A. Ramirez**. Potential treatment for nosocomial respiratory strains of extreme drug resistant acinetobacter baumannii. European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
155. S. Aliberti, A. Amir, P. Peyrani, J. A. Myers, M. Cirino, M. Saporiti, F. Blasi, **J. A. Ramirez**. Impact of neutrophil function on outcomes of community-acquired pneumonia (cap) in patients with cancer. European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
156. Raul Nakamatsu, Marty Allen, Tim Wiemken, Bryan Moffett, Marcus Zervos, and **Julio Ramirez**. Vancomycin MICs for Respiratory Isolates of Community-Acquired MRSA and Hospital Associated MRSA. European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
157. Maricar Malinis, Forest Arnold, Marty Allen, Nadia Haque, Marcus Zervos, and **Julio Ramirez**. Community-Associated Methicillin-Resistant *Staphylococcus aureus* (CA-MRSA) as a Cause of Hospital-Acquired Pneumonia. European Respiratory Society Annual Congress 2007. Stockholm, Sweden. September 15-19, 2007.
158. Uchenna Ezike, Hussain Khawaja, Raul Nakamatsu, Paula Peyrani, and **Julio Ramirez**. Anemia is Associated with Poor Clinical Outcomes in Patients with Hospital-Acquired Pneumonia. Research!Louisville 2007. October, 15-17, 2007. (Poster presentation).
159. Inem Umoren, Zehra Palanpurwala, Mary Beth Allen, Paula Peyrani, and **Julio Ramirez**. Narrowing the Spectrum of Antibiotic Therapy is not associated with Poor Clinical Outcomes in Patient with Hospital-Acquired Pneumonia. Research!Louisville 2007. October, 15-17, 2007. (Poster presentation). Winner, School of Medicine Clinical Research Fellow Award.
159. Amir Ali Amjadi, Ali Asghar Morkas, Mary Beth Allen, Paula Peyrani, and **Julio Ramirez**. Poor Adherence of Physicians with New Guidelines for Short Course Antibiotic Therapy for Hospital-Acquired Pneumonia. Research!Louisville 2007. October, 15-17, 2007. (Poster presentation).
160. V. Betti, S. Aliberti, P. Peyrani, P. Tarsia, F. Blasi, **J. Ramirez**. The pneumonia severity index (PSI) does not underestimate the severity of community-acquired pneumonia (CAP) in young patients: results from the CAPO international study. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
161. S. Aliberti, P. Peyrani, F. Blasi, P. Tarsia, L. Allegra, **J. Ramirez**. Patient characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
162. P. F. Castellotti, V. Rossetti, S. Aliberti, P. Tarsia, P. Peyrani, F. Blasi, **J. Ramirez**. Site of care for community-acquired pneumonia (CAP) patients with CRB-65 score of 0-1 and pneumonia severity index (PSI) risk class (RC) of IV-V: what to do when this discrepancy occurs. Results from the CAPO international study. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
163. **J. Ramirez**, S. Aliberti, M. Mirsaeidi, P. Peyrani, G. Filardo, G. Levy, P. Fernandez, D. Legnani, M. Mateo, M. Bodi, J. Martinez, F. Blasi, and The CAPO Investigators. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.

164. M. Mirsaeidi, P. Peyrani, J. Portillo, M. Allen, F. Arteta, J. Porras, J. Roig, E. Rodriguez, M. Rodriguez, **J. Ramirez**, and The CAPO Investigators. Female gender is associated with poor clinical outcomes in hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
165. P. Peyrani, J. Rello, R. Menendez, P. Rossi, A. Torres, F. Blasi, R. Cosentini, C. Luna, C. Feldman, **J. Ramirez**, and The CAPO Investigators. A worldwide perspective of the level of compliance with guidelines in hospitalized patients with community-acquired pneumonia: results from the CAPO cohort international study. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
166. S. Aliberti, P. F. Castellotti, A. M. Brambilla, R. Cosentini, V. Rossetti, F. Tantardini, P. Tarsia, P. Peyrani, **J. Ramirez**, F. Blasi. Reasons that justify hospitalization for community-acquired pneumonia (CAP) patients with CURB-65 score 0-1. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
167. M. Mirsaeidi, P. Peyrani, S. Aliberti, G. Filardo, F. Blasi, H. Lode, J. M. Luna, M. T. Parada, **J. Ramirez**, and The CAPO Investigators. Thrombocytosis predicts poor outcomes in patients with community-acquired pneumonia: results from the CAPO international cohort study. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
168. M. Mirsaeidi, P. Peyrani, A. Diaz Fuenzalida, J. Gonzalez, L. Marzoratti, I. Toala, L. Rivero, **J. Ramirez**, and The CAPO Investigators. Penicillin-resistant streptococcus pneumoniae is a rare etiology of community-acquired pneumonia requiring hospitalization: results from the CAPO international cohort study. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
169. M. Mirsaeidi, J. Portillo, E. Anaya, P. Peyrani, J. Guardiola, F. Arnold, R. Nakamatsu, C. Victorio, G. Aiello, M. Perez Mirabal, **J. Ramirez**, and The CAPO Investigators. Pleural effusion predicts poor outcomes in hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
170. P. Peyrani, J. Mangino, M. Zervos, D. Kett, K. Ford, E. Scerpella, **J. Ramirez**, and The IMPACT-HAP Investigators. Performance indicators to evaluate the management of patients with ventilator-associated pneumonia: results from the IMPACT-HAP study group. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
171. J. Summersgill, L. Schindler, K. Campbell, **J. Ramirez**. Indeterminate results of the quantiFERON TB gold (QFT) in hospitalized patients at risk for MTB infection / disease. European Respiratory Society Annual Congress 2008. Stockholm, Sweden. October 4-8, 2008.
172. Rama Kapoor, MD, Amirali Amjadi, MD, Timothy Wiemken, MPH, CIC, Arna Davidson, PA, Paula Peyrani, MD, Anna Huang, MD, **Julio Ramirez, MD**, Shirish Barve, PhD. Impact of Heavy Alcohol Use on the Clinical Course of HIV Diseases. Research!Louisville 2008. October, 20-24, 2008. (Poster presentation).
173. DH Kett, **JA Ramirez**, JE Manginno, MJ Zervos, P Peyrani, E Canno, AA Quartink, KD Ford, EG Scerpella, and the IMPACT-HAP Study Group. Management of Healthcare-Associated Pneumonia (HAP): Relationship of American Thoracic Society (ATS) and the Infectious Diseases Society of American (IDSA) Guideline Compliance and Mortality. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 442 (K-479)].

174. JE Mangino, P Peyrani, DK Kett, MJ Zervos, EG Scerpella, KD Ford, **JA Ramirez**, and the IMPACT-HAP Study Group. Use of Quality Indicators to Measure Compliance with ATS/IDSA Guidelines for Hospital-Acquired Pneumonia (HAP), Healthcare-Associated (HCAP) and Ventilator-Associated Pneumonia (VAP) at 4 Medical Centers: The IMPACT HAP Project. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 442 (K-480)].
175. M Mirsaeidi, P Peyrani, R Kapoor, A Amjadi, U Ezike, I Umoren, M Allen, **J Ramirez**, and the IMPACT –HAP Study Group. Predicting Mortality in Patients with Ventilator-Associated Pneumonia: The APACHE II Score versus the New IBMP-10 Score: Results from the IMPACT-HAP Study. . 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 443 (K-484)].
176. E Cano, CM Cely, AA Quartin, AS Castelblanco, DH Kett, **JA Ramirez**, JE Mangino, MJ Zervos, P Peyrani, KD Ford, EG Scerpella, and the IMPACT-HAP Study Group. Development of Renal Insufficiency and its Impact of Survival in Patients with Healthcare-Associated Pneumonia (HCAP): Ezperience at Four Academic Medical Centers. . 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 443 (K-485)].
177. P Peyrani, T Wiemken, M Mirsaeidi, M Gnono, **J Ramirez**, and the IMPACT-HAP Study Group. Variability of Hospital Cost for Patients with Ventilator-Associated Pneumonia: Results from the IMPACT-HAP Study. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 445 (K-491)].
178. M Allen, M Mirsaeidi, P Peyrani, J Mangino, M Zervos, D Kett, K Ford, E Scerpella, **J Ramirez**, and the IMPACT-HAP Study Group. Emergence of Community-Associated Methicillin-Resistant *Staphylococcus aureus* as Etiology of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: Results from the IMPACT-HAP Study. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 446 (K-494)].
179. M Mirsaeidi, P Peyrani, T Wiemken, M Gnoni, **J Ramirez**, and the IMPACT-HAP Study Group. Making the Microbiological Diagnosis in Patients with Healthcare-Associated Pneumonia, Hospital-Acquired Pneumonia, and Ventilator-Associated Pneumonia: Role of Bacteremia. Results from the IMPACT-HAP Study. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 446 (K-496)].
180. NA Haque, L Cahuayme Zuniga, P Osaki Kiyan, S Patel, C Manierski, K Reyes, P Peyrani, **J Ramirez**, J Mangino, D Kett, K Ford, EG Scerpella, MJ Zervos, and the IMPACT-HAP Study Group. Relationship of MIC to Vancomycin on Outcome of Methicillin-Resistant *Staphylococcus aureus* Health Care-Associated and Hospital-Acquired Pneumonia. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 455 (K-531)].
181. EG Scerpella, KD Ford, P Peyrani, DH Kett, JE Mangino, MJ Zervos, **JA Ramirez**, and the IMPACT-HAP Study Group. Thrombocytopenia in Intensive Care Unit (ICU) Patients with Hospital-Acquired (HAP), Ventilator-Associated (VAP), and Healthcare-Associated Pneumonia (HCAP) due to Methicillin-Resistant *Staphylococcus aureus* (MRSA) Treated with Linezolid and Vancomycin: Experience at Four Academic Medical Centers. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 455 (K-532)].
182. M Repetto, F Saavedra, D Pryluka, A Lambierto, P Peyrani, **J Ramirez**. Combination Therapy is not needed for the Treatment of Hospitalized Patients with Pneumococcal Pneumonia: Results from the CAPO International Study. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 598 (L-663)].

183. P Peyrani, S Aliberti, M Mirsaedi, G Filardo, F Blasi, J Bordon, **J Ramirez**, and the CAPO Investigators. Acute Myocardial Infarction in Hospitalized Patients with Community-Acquired Pneumonia: Results from the CAPO International Cohort Study. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 609 (L-915)].
184. M Allen, J Portillo, C Roberts D Seligson, A Chen, M Zervos, P Peyrani, **J Ramirez** and the BAJIO Study Group. Emergence of Community-Associated Methicillin Resistant *Staphylococcus aureus* as Etiology of Osteomyelitis: Results from the BAJIO Study. 48th Annual ICAAC/IDSA Meeting. Washington, DC, October 25-28, 2008. [Publication Page: 613 (L-1505)].
185. Kapoor, R, Wiemken,T, Davidson, A, Peyrani, P, Nakamatsu, R, Barve, S, **Ramirez, J**. Impact of Heavy Alcohol Use on HIV Disease Progression in the ERA of HAART. 47th Annual Meeting of Infectious Diseases Society of America; Poster no. 348, oct 30, 2009.
186. Kapoor, R, Wiemken,T, Peyrani, P, Allen,M, **Ramirez, J**, Arnold,F. Clinical Outcomes of Patients Hospitalized with Community-Acquired Pneumonia due to CA-MRSA vs. MSSA. 47th Annual Meeting of Infectious Diseases Society of America; Poster no. 961, Oct 31, 2009.
187. Malinis,M, Myers, J, Bordon, J, Peyrani, P, Kapoor, R, Nakamatsu, R, Lopardo, G, Torres, A, Feldman, C, Allen, M, Arnold, F, **Ramirez, J**. Clinical Outcomes of HIV-Infected Patients Hospitalized with Community-Acquired Pneumonia:Results from CAPO International Study Group. 47th Annual Meeting of Infectious Diseases Society of America; Poster no. 953, Oct 31, 2009.
188. Donabedian SM, Haque N, Perri M, Moore C, Peyrani P, **Ramirez J**, File Jr. T, Kett DH, Mangino JE, Scerpella E, Ford K, Zervos M. Laboratory Characteristics and Outcomes of MRSA Hospital-Acquired, Healthcare-Associated, and Ventilator-Associated Pneumonia: The IMPACT-HAP Project. IDSA 48th Annual Meeting, Vancouver, BC. October 21-24, 2010 [Abstract # 468]
189. Haque N, Osaki-Kiyan P, Perri M, Moore C, Peyrani P, **Ramirez J**, File Jr. T, Scerpella E, Ford K, Zervos M. AUC/MIC Calculated by Two Methods and Outcome in Hospital-Acquired, Health Care-Associated, and Ventilator-Associated Methicillin-Resistant *Staphylococcus aureus* (MRSA) Pneumonia. IDSA 48th Annual Meeting, Vancouver, BC. October 21-24, 2010 [Abstract # 865]
190. Pasquale TR, Salstrom SJ, Jabrocki B, Wiemken T, Peyrani P, Haque N, Zervos M, **Ramirez J**, Scerpella E, Ford K, File Jr. T, IMPACT HAP Study Group. Molecular Evaluation of MRSA in Patients with Nosocomial Pneumonia: Early Onset versus Late Onset. IDSA 48th Annual Meeting, Vancouver, BC. October 21-24, 2010 [Abstract # 463]
191. Welch VL, Kett DH, Scerpella E, Peyrani P, Ford K, Mangino JE, Zervos M, **Ramirez J**. The Impact of Gender on Outcomes of Critically Ill Patients with Hospital-Acquired Pneumonia. IDSA 48th Annual Meeting, Vancouver, BC. October 21-24, 2010 [Abstract # 465]
192. Pasquale T.R, Salstrom S.J, Jabrocki B, Wiemken T, Peyrani P, Haque N, Zervos M.J, **Ramirez J.A**, Scerpella E, Ford K.D, File Jr. T.M, IMPACT HAP Study Group. Outcomes and Differences of MRSA Nosocomial Pneumonia: Early Onset vs. Late Onset. The American Thoracic Society International Conference, Denver, Colorado. May 13-18, 2011. [Abstract 19213]
193. Christensen D, Ostrowsky B, CillónizC, Baillargeon C, de Vedia L, Herbert V, Polverino E, Feldman C, Torres A, Weiss K, von Gottberg A, Wiemken T, Peyrani P, Gialanella P, Pirofski L, **Ramirez J**, and CAPO Investigators. Relationship of *Streptococcus pneumoniae* Serotypes with Clinical Failure in Hospitalized Patients with Community-acquired Pneumonia. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011 [Abstract # 1224]

194. File Jr. T, Peyrani P, Ford KD, Welch VL, Scerpella E, **Ramirez J.** Evaluating Healthcare-Associated Pneumonia (HCAP) in Intensive Care: A Retrospective Analysis of 278 Patients. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011 [Abstract # 368]
195. Seshabhattar P, Ananthakrishnan P, Peyrani P, Wiemken T, Arnold F, Nakamatsu R, Kapoor R, **Ramirez J.** Payer Status Is Not a Predictor for Early HIV Care Entry. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011 [Abstract # 461]
196. Kett DH, Welch VL, Peyrani P, Scerpella E, Ford KD, **Ramirez J.** Pneumonia in Intensive Care Unit Patients: Incidence, Risk Factors and Outcomes Related to Multidrug-Resistant Organisms. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011 [Abstract # 370]
197. Peyrani P, Wible M, Ford KD, Huang D, Wiemken T, **Ramirez J.** Risk Factors Associated with Mortality in Patients with Ventilator-Associated Pneumonia (VAP): An Evaluation of Patients Enrolled in an International Trial for the Treatment of Nosocomial Pneumonia (NP). IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011 [Abstract # 362]
198. Wiemken T, Peyrani P, Arnold FW, Jonsson CB, Bryant K, Carrico RM, McKinney WP, Chung D, Chu YK, Summersgill J, Nakamatsu R, Simms J, Stockton S, Merrill T, Pinson R, **Ramirez JA.** Severe Influenza Pneumonia Surveillance: Clinical and Translational Epidemiology. International Society for Disease Surveillance. Atlanta, GA. December 6-8, 2011.
199. Peyrani P, Nahas A, Giovini V, Meza Ortiz C, Wiemken T, Chaves SS, Fry A, **Ramirez JA.** Respiratory viruses are significant etiologic agents in hospitalized patients with lower respiratory tract infections: results from the rapid empiric treatment with Oseltamivir study (RETOS). American Thoracic Society, San Francisco, CA, May 18-23, 2012.
200. Uriarte S, Arnold FW, Fernandez-Botran R, Rane M, Peyrani P, Wiemken T, Bordon J, **Ramirez JA.** Translational study linking neutrophil activation and cytokine responses with clinical outcomes in patients with community-acquired pneumonia. American Thoracic Society, San Francisco, CA, May 18-23, 2012.
201. Wiemken T, Faughender A, Clay J, Carrico R, **Ramirez J.** Targeted, Daily Environmental Disinfection with Clorox® Dispatch® for the Prevention of Hospital-Associated *Clostridium difficile* and *Acinetobacter baumannii*. Association for Professionals in Infection Control. San Antonio, TX, June 4-6 2012.
202. Ford K, Peyrani P, Wiemken T, Scerpella E, Zervos M, Kett D, File T, Stein G, **Ramirez J.** Hematologic and renal function evaluation of linezolid and vancomycin patients with VAP due to MRSA: results from the IMPACT-HAP study. IDWeek 2012, San Diego, CA, October 17-21, 2012.
203. Wiemken T, Peyrani P, Ford K, Scerpella E, Zervos M, Kett D, File T, Stein G, **Ramirez J.** Resource utilization in patients with VAP due to MRSA treated with linezolid versus vancomycin: results from the IMPACT-HAP study. IDWeek 2012, San Diego, CA, October 17-21, 2012.
204. Wiemken T, Peyrani P, Chaves S, Fry A, **Ramirez J.** Impact of temperature and humidity on the incidence of influenza in hospitalized patients with lower respiratory tract infections. IDWeek 2012, San Diego, CA, October 17-21, 2012.
205. Peyrani P, Wiemken T, Fry A, Chaves S, **Ramirez J.** Respiratory viruses are significant etiologic agents in hospitalized patients with lower respiratory tract infections. IDWeek 2012, San Diego, CA, October 17-21, 2012.

206. Wiemken T, Peyrani P, Summersgill J, Chaves S, Erdman, Fry A, **Ramirez J**. Human rhinovirus detection among adults hospitalized with lower respiratory tract infections. IDWeek 2012, San Diego, CA, October 17-21, 2012.
207. Fernandez F, Britto J, Otero D, Baez J, Rivera K, Rodriguez L, Kelley R, Wiemken T, Peyrani P, **Ramirez J**. Impact of Oseltamivir Treatment on Clinical Outcomes of Hospitalized Patients with Community Acquired Pneumonia due to Influenza. Research Louisville, Louisville, KY, September 24-27, 2013
208. Baez J, Pacholski E, Kolikonda M, Rodriguez L, Fernandez F, Kelley R, Wiemken T, Peyrani P, **Ramirez J**, Cavallazzi R. Mortality differences among hospitalized patients with severe community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Research Louisville, Louisville, KY, September 24-27, 2013.
209. Arnold F, **Ramirez J**, Botran R, Rane M, Uriarte S, Kelley R, Wiemken T, Peyrani P, Bordon J. Macrolide Immunomodulation and Outcomes in Hospitalized Patients with Community-Acquired Pneumonia. Research Louisville, Louisville, KY, September 24-27, 2013.
210. Pacholski E, Baez J, Rodriguez L, Otero D, Rivera K, Kolikonda M, Kelley R, **Ramirez J**, Carrico R, Wiemken T. The Evaluation of the Effectiveness of the trivalent influenza vaccine for the prevention of hospitalizations due to influenza pneumonia; results from the Rapid Empiric Treatment with Oseltamivir Study. Research Louisville, Louisville, KY, September 24-27, 2013.
211. Kelley R, Wiemken T, Peyrani P, Carrico R, Curran D, Khan M, Pacholski E, Coats D, **Ramirez J**. Challenges with creating a Clinical and Translational Research Support Center in the University of Louisville Department of Medicine. Research Louisville, Louisville, KY, September 24-27, 2013.
212. Wiemken T, Jonsson C, Kellye R, Peyrani P, Carrico R, **Ramirez J**. Prior Influenza Vaccination is associated with Increased Detection of Non-Influenza Respiratory Viruses in Hospitalized Patients with Lower Respiratory Tract Infections: Results from the Rapid Empiric Treatment with Oseltamivir Study. Research Louisville, Louisville, KY, September 24-27, 2013.
213. Calderon C, Raghuram A, Wiemken T, Kellye R, Otero D, **Ramirez J**, Peyrani P. 1. Assessing the response to hepatitis B immunizations in HIV-1 positive adults. Research Louisville, Louisville, KY, September 24-27, 2013.
214. Westhusing K, Balcom D, Macchiavelli A, Britto J, Hussainy R, Kolkonda M, Kelley R, **Ramirez J**, Carrico R, Wiemken T. Understanding Why Patients Accept Vaccination: A Socio-Behavioral Approach at the University of Louisville Vaccine and International Travel Center. The University of Louisville Refugee Health Program. Research Louisville, Louisville, KY, September 24-27, 2013.
215. Cavallazzi R, Kolkonda M, Kadali S, Fernandez F, Britto J, Hussainy R, Gnoni M, Kelley R, Wiemken T. **Ramirez J**. Treatment of Health-Care Associated Pneumonia and Outcomes. Research Louisville, Louisville, KY, September 24-27, 2013.
216. Wiemken T, Rudin S, Jacobs M, Bonom R, Kelley R, Pacholski E, **Ramirez J**. A single genotype of multidrug resistant (MDR) *Acinetobacter baumannii* expresses multiple antibiotic susceptibility phenotypes. IDWeek 2013, San Francisco, CA. October 2-6, 2013. Poster 1624.
217. Wiemken T, Pachoski E, Kelley R, Carrico R, Peyrani P, Aliberti S, Blasi F, Gonzalez R, Lopardo G, **Ramirez J**. The impact of gender on the effectiveness of the 23-valent pneumococcal polysaccharide vaccine in the elderly: Results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. IDWeek 2013, San Francisco, CA. October 2-6, 2013

218. Wiemken T, Pacholski E, Kelley R, Clay J, Daniels K, Bromilow M, **Ramirez J**. Comparing cleaning and disinfection using the traditional cloth and bucket method versus the ready to use wipe method: process compliance and time-related costs. IDWeek 2013, San Francisco, CA. October 2-6, 2013. Poster 1701.
219. Peyrani P, Wiemken T, Kelley R, Zervos M, Kett D, File T, Stein G, Ford K, Welch V, **Ramirez J**. Time to clinical stability in patients with ventilator-associated pneumonia (VAP) due to methicillin-resistant *Staphylococcus aureus* (MRSA) treated with linezolid versus vancomycin: results from the IMPACT-HAP study. IDWeek 2013, San Francisco, CA. October 2-6, 2013. Poster 773.
220. Peyrani P, Wiemken T, Kelley R, Zervos M, Kett D, File T, Stein G, Ford K, Welch V, **Ramirez J**. Association of organ dysfunction with clinical failure in Patients with patients with ventilator-associated pneumonia (VAP) due to methicillin-resistant *Staphylococcus aureus* (MRSA) treated with linezolid versus vancomycin: results from the IMPACT-HAP study. IDWeek 2013, San Francisco, CA. October 2-6, 2013. Poster 772.
221. Perez San Juan J, Rodriguez Hernandez L, Uriarte S, Kelley R, Wiemken T, Fernandez-Botran R, Gnoni M, Peyrani P, Bordon J, Rane M, Arnold F, **Ramirez J**. Neutrophil function in elderly patients hospitalized with community-acquired pneumonia (CAP): Results from the Community-Acquired Pneumonia Inflammatory Study Group (CAPISG). IDWeek 2013, San Francisco, CA. October 2-6, 2013. Poster 1321.
222. Beavin L, Otero D, Britto J, **Ramirez J**, Wiemken T, Kelley R, Peyrani P. Obese HIV positive females are at decreased risk for development of opportunistic infections. IDWeek 2013, San Francisco, CA. October 2-6, 2013. Poster 42238.
223. Gupta R, Harati H, Fernandez P, Jimenez P, Peyrani P, Wiemken T, Burdette S, Schuetz P, Haubitz S, **Ramirez J**, Bordon J. Clinical outcomes of patients with diabetes mellitus hospitalized with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. IDWeek 2013, San Francisco, CA. October 2-6, 2013. Poster 888.
224. Khan M, Wiemken T, Curran D, Kelley R, Pacholski E, Carrico R, Peyrani P, Ramirez J. The Impact of Temperature and Absolute Humidity on the Incidence of Influenza in Hospitalized Patients with Lower Respiratory Tract Infection. APIC International Conference. June 2014
225. Kelley R, Wiemken T, Curran D, Khan M, Pacholski E, Carrico R, **Ramirez J**. Risk of Acquiring Carbapenem-resistant Klebsiella Pneumoniae from Bed Contact in a Long-term Care Hospital. APIC International Conference. June 2014.
226. Wiemken T, Curran D, Khan M, Kelley r, Pacholski E, Carrico R, **Ramirez J**. What is the Role of Improved Hydrogen Peroxide in the Operating Room? APIC International Conference. June 2014
227. Pacholski E, Wiemken T, Gonzales J, Rodriguez Hernandez L, Otero D, Rivera Contreras K, Kolikonda M, Kelley, **Ramirez J**, Carrico R. The Evaluation of the Effectiveness of Trivalent Influenza Vaccine for the Prevention of Hospitalizations Due to Influenza Pneumonia. APIC International Conference. June 2014.
228. Carugati M, Aliberti S, Franzetti F, Wiemken T, Kelley R, Peyrani P, **Ramirez J**. De-escalation therapy is safe in septic patients with community-acquired pneumonia. Interscience Conference on Antimicrobial Agents and Chemotherapy 2014 Annual Meeting. Washington DC, September 5-9, 2014.

229. Buckner K, Kelley RR, Binford L, Guinn B, Gonzalez J, Ackerman C, Peyrani P, Carrico R, **Ramirez J**, Wiemken T. The economic burden of adult hospitalization due to pneumonia in acute care hospitals in Jefferson County. Research Louisville. September 2014
230. Ackerman C, Guinn B, Peyrani P, Wiemken T, Kelley RR, Arnold F, Carrico R, **Ramirez J**. Patients hospitalized with lower respiratory tract infections in Jefferson County: The impact of population density. Research Louisville. September 2014.
231. Ahmed M, Rodriguez L, Perez J, Guinn B, Pena S, Fuentes A, Elkhawas I, Kincaid J, Wiemken T, **Ramirez J**. Streptococcus pneumoniae Serotypes in Hospitalized Patients with Community- Acquired Pneumonia in Jefferson County. Research Louisville. September 2014.
232. Elkhawas I, Reyes E, Mattingly W, Mohiuddin A, Arnold F, Carrico R, Peyrani P, Wiemken T, Kelley RR, **Ramirez J**. Impact of Macrolides on Clinical Outcomes of Hospitalized Patients with Community-Acquired Pneumonia and Non-Streptococcus pneumoniae Bacteremia: Results from the CAPO International Study. Research Louisville. September 2014
233. Fernandez F, Britto J, Beavin L, Husainy R, Harting J, Nakamatsu R, Arnold F, **Ramirez J**, Wiemken T, Kelley RR, Ramirez J. Characteristics, Etiology, and Clinical Outcomes of Patients with Vertebral Osteomyelitis. Research Louisville. September 2014.
234. Gonzalez J, Ahmed M, Pena S, Srinivasan K, King D, Elkhawas I, Kelley RR, Peyrani P, Wiemken T, **Ramirez J**. A Population-Based Study In Jefferson County to Estimate the Number of Hospitalizations due to Community-Acquired Pneumonia in the United States. Research Louisville. September 2014.
235. Guinn B, Wiemken T, Kelley RR, Binford L, Arnold F, Carrico R, Peyrani P, Buckner K, Ackerman C, **Ramirez J**. Levels of Air Pollution in Jefferson County, Kentucky Are Associated with Increased Risk for Lower Respiratory Tract Infection Hospitalizations. Research Louisville. September 2014.
236. Kolikonda M, Reyes E, Rivera R, Ayoubi R, Mattingly W, Arnold F, Nakamatsu R, Peyrani P, Wiemken T, **Ramirez J**. Neuro-Psychiatry Diseases Predisposing to Mental Status Changes in Patients with Community-Acquired Pneumonia. Research Louisville. September 2014.
237. Mattingly W, Kelley RR, Wiemken T, Buckner K, Guinn B, Binford L, Grassman M, Kincaid J, Lanceta J, **Ramirez J**. Development Of Applications To Facilitate Clinical Research: The Pneumonia In Jefferson County Clinical Research Enrollment App. Research Louisville. September 2014.
238. Pena S, Perez R, Binford L, Kincaid J, Fernandez F, Harting J, Arnold F, Wiemken T, Carrico R, **Ramirez J**. Post Traumatic Osteomyelitis: A Reflection of the Current Jefferson County Trauma Epidemic. Research Louisville. September 2014
239. Perez J, Harting J, **Wiemken T**, Kelley RR, Peyrani P, Ramirez J. The association of endocarditis with vertebral osteomyelitis: A Case Report from the Bone and Joint International Organization Study. BAJIO. Research Louisville. September 2014.
240. Perez Rivera R, Guinn B, Wiemken T, Kelley RR, Ahmed M, Gonzalez J, Lanceta J, Salunkhe V, Binford L, Ramirez J. Impact of economic factors on the incidence of hospitalization for lower respiratory tract infection in Jefferson County. Research Louisville. September 2014.
241. Salunkhe V, Rodriguez L, Gonzalez J, Khalifa A, Gibson R, Mohiuddin A, Lanceta J, Kolikonda M, **Wiemken T**, Ramirez J. Is Time of the Day or Day of the Week Associated with Hospitalizations due to Community- Acquired Pneumonia? Research Louisville. September 2014.

242. Srinivasan K, Reyes E, Rivera R, Mattingly W, Buckner K, Carrico R, Peyrani P, Kelley RR, Wiemken T, Ramirez J. Challenges in Multicenter, Community-Based Clinical Research in Jefferson County, KY: A Method for Auditing the Consent Process. Research Louisville. September 2014.
243. Bininashvili T, Perez San Juan J, Gnoni M, Steinbrunner J, Rodriguez-Hernandez L, Kelley RR, Wiemken T, Gonzales Y, Friedstorm S, **Ramirez J**. Community Acquired Pneumonia in Pregnancy: Impact of Influenza on Clinical Outcomes. Research Louisville. September 2014.
244. Britto J, Beavin L, Husainy R, Fernandez F, Harting J, Kelley RR, Wiemken T, **Ramirez J**, Hicks A, Kim K. Clinical Characteristics, Microbiology, and Outcomes in Patients with Diabetic Foot Osteomyelitis. Research Louisville. September 2014.
245. Harting J, Kelley RR, Wiemken T, Christensen D, Gnoni M, **Ramirez J**. High-Dose Ertapenem is Safe and Effective for Treatment of Osteomyelitis and Prosthetic Joint Infections. Research Louisville. September 2014.
246. Hernandez Rodriguez L, Perez San Juan J, Kelley R, Wiemken T, Fernandez Botran R, Gnoni M, Peyrani P, Bordon J, Rane M, Arnold F, **Ramirez J**, Uriarte S. Innate pulmonary response to community-acquired pneumonia (CAP) in patients with chronic obstructive pulmonary disease (COPD): Results from the community-acquired pneumonia inflammatory study group (CAPISG). IDWeek 2014, Philadelphia PA, October 8-12, 2014
247. Arnold F, **Ramirez J**, Fernandez Botran R, Uriarte S, Kelley R, Wiemken T, Peyrani P, Bordon J. Macrolide use and innate immunity components in hospitalized patients with community-acquired pneumonia. IDWeek 2014, Philadelphia PA, October 8-12, 2014.
248. Perez San Juan J, Curran D, Rodriguez Hernandez L, Kelley R, Wiemken T, Arnold F, Nakamatsu R, Raghuram A, Peyrani P, Summersgill J, Carrico R, **Ramirez J**. Incidence of cardiovascular events in patients with influenza pneumonia or pneumonia due to other etiologies. IDWeek 2014, Philadelphia PA, October 8-12, 2014.
249. Woodford M, Mehta I, Burk M, Middaugh M, Dee S, Wiemken T, Cavallazzi R, **Ramirez J**. Viral pneumonia in patients with community-acquired pneumonia. American College of Chest Physicians 2014 National Meeting, Austin, Texas, October 25-30, 2014.
250. Mattingly WA, Kelley RR, Chariker JH, Wiemken TL, **Ramirez J**. An iterative workflow for creating biomedical visualizations using Inkscape and D3.js. 14th Annual UT-KBRIN Bioinformatics Summit. March 20-22, 2015. Buchanan, TN.
251. Powell W, Binford L, Mattingly W, Kelley R, Guinn B, Peyrani P, Carrico R, **Ramirez J**, Wiemken T. Disinfectant sprays or wipes: Applications in the setting of behavioral health. Association for Professionals In Infection Control June 27-29, 2015. Nashville TN.
252. Harting J, Fernandez F, Kelley RR, Wiemken TL, Peyrani P, **Ramirez J**. A Pilot Study Evaluating Televancin for the Treatment of Methicillin-Resistant Staphylococcus aureus Osteomyelitis: Clinical Outcomes and Safety. ID Week 2015, San Diego, CA, October 7-11, 2015.
253. **Ramirez J**, Wiemken T, Peyrani P, Kelley R, Carrico R and the Louisville Pneumonia Study Group. RISK FOR HOSPITALIZATION DUE TO COMMUNITY-ACQUIRED PNEUMONIA (CAP) IN NON-ELDERLY PATIENTS WITH COMORBID CONDITIONS: THE LOUISVILLE PNEUMONIA STUDY. ISPPD, Glasgow, Scotland, June 23-26, 2016.
254. **Ramirez J**, Wiemken T, Peyrani P, Kelley R, Carrico R and the Louisville Pneumonia Study Group. A POPULATION-BASED STUDY TO DEFINE THE INCIDENCE AND COST OF ADULT HOSPITALIZATIONS DUE TO COMMUNITY-ACQUIRED PNEUMONIA IN THE UNITED

- STATES: THE UNIVERSITY OF LOUISVILLE PNEUMONIA STUDY. ISPPD, Glasgow, Scotland, June 23-26, 2016.
255. **Ramirez J**, Wiemken T, Peyrani P, Kelley R, Carrico R and the Louisville Pneumonia Study Group. A Number of Deaths in Patients Hospitalized with Community-Acquired Pneumonia In the United States (US): The University of Louisville Pneumonia Study. ISPPD, Glasgow, Scotland, June 23-26, 2016.
 256. **Ramirez J**, Wiemken T, Peyrani P, Kelley R, Carrico R and the Louisville Pneumonia Study Group. Annual Number of Rehospitalizations due to Community-Acquired Pneumonia in the United States: The University of Louisville Pneumonia Study. ISPPD, Glasgow, Scotland, June 23-26, 2016.
 257. **Ramirez J**, Wiemken T, Peyrani P, Kelley R, Carrico R and the Louisville Pneumonia Study Group. Influence of Race and Income Level on the Incidence of Hospitalizations due to Community-Acquired Pneumonia: The University of Louisville Pneumonia Study. ISPPD, Glasgow, Scotland, June 23-26, 2016.
 258. **Ramirez J**, Wiemken T, Peyrani P, Kelley R, Carrico R and the Louisville Pneumonia Study Group. Challenges in Conducting Epidemiological Studies to Define Incidence of Patients Hospitalized with Community-Acquired Pneumonia: The University of Louisville Pneumonia Study. ISPPD, Glasgow, Scotland, June 23-26, 2016.
 259. Vega AR, Loban A, Srinivasan K, Furmanek S, English C, Bishop M, Spencer C, Truelove D, **Ramirez J**, Raghuram A, Peyrani P. Gender Differences in Virologic Response after Antiretroviral Therapy in Treatment-naïve HIV-infected Individuals: Results from the 550 Clinic HIV Cohort Study. InOpen forum infectious diseases. (October 2017) Vol. 4, No. suppl_1, pp. S432-S433. US: Oxford University Press.
 260. **Ramirez JA**, Wiemken TL, Peyrani P, University of Louisville Pneumonia Study Group. Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology & Mortality. ID Week 2017, San Diego, CA, October 4-8, 2017.
 261. **Ramirez J**. Burden of Community-acquired Pneumonia due to Pcv-13streptococcus pneumoniaeserotypes Among Hospitalized Adults in the United States. InOpen Forum Infectious Diseases. (October 2017) Vol. 4, p. S573. Open Forum Infectious Diseases.
 262. Peyrani P, Quinn A, Furmanek S, **Ramirez J**, Swerdlow D. Burden of Invasive and Non-invasive Group B Streptococcal Infections in hospitalized adults, Louisville, Kentucky: preliminary analysis of a large population-based study. San Francisco, CA, October 3-8, 2018.
 263. Gearhart A, Furmanek S, Cavallazzi R, **Ramirez J**. PREDICTING ADMISSION TO THE ICU IN COMMUNITY-ACQUIRED PNEUMONIA. Chest. 2018 Oct;154(4):145A
<https://doi.org/10.1016/j.chest.2018.08.126>.

BOOKS

1. **Ramirez JA**, Morrissey I, Ambler JE. *Clinician's Manual on Serious Infections and Fluoroquinolones*. London: Science Press, 2002.
2. **Ramirez, JA**. *Community-Acquired Pneumonia. A Plan for Implementing National Guidelines at the Local Hospital Level*. Philadelphia: Lippincott Williams & Wilkins; 2003.
3. **Ramirez, JA**. *Switch Therapy in Hospitalized Patients with Serious Infections*. Pharmacia Corp., 2003.

BOOK CHAPTERS

1. **Ramirez J**. Chapter 66 "Hospital-Acquired Infections". *Principles and Practice of Medical Therapy in Pregnancy: Third Edition*. Norbert Gleicher, M.D., Editor. 1998.
2. **Ramirez Julio A**. Chapter "*Haemophilus influenzae* Pneumonia". *Respiratory Infections*, Second Edition. Niederman, Sarosi, and Glassroth, editors. Lippincott Williams & Wilkins, Philadelphia, June, 2000. Pages 371-374.
3. **Ramirez JA**, Summersgill JT. Community-Acquired Pneumonia Due to *Chlamydia pneumoniae*. In: Marrie TJ, editor. *Community-Acquired Pneumonia*. Boston (MA): Springer; 2002. https://doi.org/10.1007/0-306-46834-4_31
4. **Ramirez Julio A**. Chapter "Legionellosis". *Conn's Current Therapy 2003*. Elsevier Science; 2003. Pages 260-2.
5. **Ramirez Julio A**. Chapter "Community-Acquired Pneumonia in Adults". *Primary Care: Update on Infectious Diseases*. Richard I. Haddy, MD and Karen W. Krigger MD, editors. Elsevier Science, March, 2003. Pages 155-171.
6. **Ramirez, J.A**. Chapter "Processes of Care for Community-Acquired Pneumonia". In: *Infectious Disease Clinics of North America*. Davis C., ed. W.B. Saunders Co., Publisher, December, 2004; 18(4):853-859.
7. **Ramirez, J.A**. Chapter "Early Discharge Strategies: Role of Transitional Therapy Programs". In: *Antibiotic Optimization: Concepts and Strategies In Clinical Practice*. Robert C. Owens, Jr., Paul G. Ambrose, and Charles H. Nightingale, editors. Marcel Dekker, New York, Publisher, February, 2005. Pages 431-449.
8. **Ramirez, Julio A**. Chapter "Legionellosis (Legionnaires' Disease and Pontiac Fever)". In: *Conn's Current Therapy 2013*. Elsevier Science 2013. Pages 364-365.
9. Peyrani P, **Ramirez JA**. Chapter "Nontuberculous mycobacterial pulmonary infections" In: *Pulmonary Complications of Hiv*. Ers Monograph, Number 66. Sheffield: European Respiratory Society, 2014.
10. Wiemken, T, Carrico, R., Peyrani, P., **Ramirez, J.A**. In Blasi & Dimopoulos (Eds.). Chapter 17. *Intensive Care Unit-associated Infections: Pathogenesis, Management, and Prevention*. Textbook of Respiratory and Critical Care Infections. Jaypee Brothers Medical Publishers. 2015.
11. Cavallazzi R, **Ramirez JA**. Chapter "Combination antibiotic therapy and synergy in HAP and VAP". *European Respiratory Society. Anti-infectives and the Lung*. J. D Chalmers, and Mathias W Pletz. Ers Monograph, Number 75. Sheffield: European Respiratory Society, 2017. Mar;75:302-11.